<SEC-DOCUMENT>0001193125-22-247108.txt : 20220919
<SEC-HEADER>0001193125-22-247108.hdr.sgml : 20220919
<ACCEPTANCE-DATETIME>20220919161702
ACCESSION NUMBER:		0001193125-22-247108
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20220914
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220919
DATE AS OF CHANGE:		20220919

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IDEAYA Biosciences, Inc.
		CENTRAL INDEX KEY:			0001676725
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474268251
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38915
		FILM NUMBER:		221250808

	BUSINESS ADDRESS:	
		STREET 1:		7000 SHORELINE COURT, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-443-6209

	MAIL ADDRESS:	
		STREET 1:		7000 SHORELINE COURT, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Ideaya Biosciences, Inc.
		DATE OF NAME CHANGE:	20160609
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d382258d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:idya="http://www.ideayabio.com/20220914" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2022-09-14_to_2022-09-14">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-09-14_to_2022-09-14">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-09-14_to_2022-09-14">0001676725</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="idya-20220914.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-09-14_to_2022-09-14"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-14</xbrli:startDate> <xbrli:endDate>2022-09-14</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-09-14_to_2022-09-14">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-09-14_to_2022-09-14" format="ixt:datemonthdayyearen">September 14, 2022</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-09-14_to_2022-09-14">IDEAYA Biosciences, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-09-14_to_2022-09-14" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-09-14_to_2022-09-14">001-38915</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-09-14_to_2022-09-14">47-4268251</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification Number)</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-09-14_to_2022-09-14">7000 Shoreline Court</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2022-09-14_to_2022-09-14">Suite 350</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-09-14_to_2022-09-14">South San Francisco</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-09-14_to_2022-09-14" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-09-14_to_2022-09-14">94080</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including Zip Code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-09-14_to_2022-09-14">(650)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-09-14_to_2022-09-14">443-6209</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-09-14_to_2022-09-14" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-09-14_to_2022-09-14" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-09-14_to_2022-09-14" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-09-14_to_2022-09-14" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-09-14_to_2022-09-14">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-09-14_to_2022-09-14">IDYA</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">The Nasdaq Global Select Market</span> </span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-09-14_to_2022-09-14" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2022-09-14_to_2022-09-14" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">a) Underwriting Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 14, 2022, IDEAYA Biosciences, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with J.P.&#160;Morgan Securities LLC, Jefferies LLC, and Citigroup Global Markets Inc., as representatives (the &#8220;Representatives&#8221;) of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;), pursuant to which the Company agreed to issue and sell 7,619,048 shares (the &#8220;Shares&#8221;) of its common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), to the Underwriters (the &#8220;Offering&#8221;). The price to the public in this offering is $10.50 per Share. The Underwriters have agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $9.87 per Share. In addition, under the terms of the Underwriting Agreement, the Company granted the Underwriters the option, for 30 days, to purchase up to 1,142,857 additional shares of Common Stock at the public offering price (the &#8220;Underwriters&#8217; Option&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering was made under a prospectus supplement and related prospectus filed with the Securities and Exchange Commission pursuant to the Company&#8217;s effective shelf registration statement on Form <span style="white-space:nowrap">S-3,</span> as amended (Registration No. <span style="white-space:nowrap">333-254606).</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Underwriting Agreement, the Company agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute to payments that the Underwriters may be required to make because of such liabilities. The Company, the Company&#8217;s directors and executive officers and one of its affiliated holders also agreed not to sell or transfer any Common Stock without first obtaining the written consent of the Representatives on behalf of the Underwriters, subject to certain exceptions as described in the prospectus supplement, for 60 days after the date of the Prospectus, as defined in the Underwriting Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 19, 2022, the Offering closed and the Company completed the sale and issuance of an aggregate of 8,761,905 shares of Common Stock, including the exercise in full of the Underwriters&#8217; Option. The Company received net proceeds of approximately $86.0 million, after deducting the Underwriters&#8217; discounts and commissions and estimated offering expenses payable by the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing descriptions of the Underwriting Agreement and <span style="white-space:nowrap">lock-up</span> arrangements do not purport to be complete and are qualified in their entirety by reference to such exhibit. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the opinion of Latham &amp; Watkins LLP relating to the validity of the securities issued in the Offering is filed herewith as Exhibit 5.1. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(d) Exhibits. </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d382258dex11.htm">Underwriting Agreement, dated as of September 14, 2022, among IDEAYA Biosciences, Inc. and J.P. Morgan Securities LLC, Jefferies LLC, and Citigroup Global Markets Inc., as representatives of the several underwriters named therein. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d382258dex51.htm">Opinion of Latham &amp; Watkins LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d382258dex51.htm">Consent of Latham &amp; Watkins LLP (included in Exhibit 5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">IDEAYA BIOSCIENCES, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: September 19, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Yujiro Hata</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Yujiro Hata</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d382258dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Execution Version </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IDEAYA
Biosciences, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7,619,048 Shares of Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Underwriting Agreement </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">September&nbsp;14, 2022 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CITIGROUP GLOBAL MARKETS INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the several Underwriters listed in </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 1 hereto </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Citigroup Global Markets Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">388 Greenwich Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10013 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IDEAYA Biosciences,
Inc., a Delaware corporation (the &#147;Company&#148;), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the &#147;Underwriters&#148;), for whom you are acting as representatives (the &#147;Representatives&#148;),
an aggregate of 7,619,048 shares of common stock, par value $0.0001 per share (&#147;Common Stock&#148;), of the Company (the &#147;Underwritten Shares&#148;). In addition, the Company proposes to issue and sell, at the option of the Underwriters,
up to an additional 1,142,857 shares of Common Stock of the Company (the &#147;Option Shares&#148;). The Underwritten Shares and the Option Shares are herein referred to as the &#147;Shares.&#148; The shares of Common Stock of the Company to be
outstanding after giving effect to the sale of the Shares are referred to herein as the &#147;Stock.&#148; </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the several Underwriters concerning the
purchase and sale of the Shares, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Registration Statement</U>. The Company has prepared and filed with the Securities and
Exchange Commission (the &#147;Commission&#148;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Securities Act&#148;), a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-254606),</FONT> including a prospectus, relating to the Shares. Such registration statement, as amended at the time it became effective, including the
information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness (&#147;Rule 430 Information&#148;), is referred to herein as the &#147;Registration
Statement&#148;; and as used herein, the term &#147;Preliminary Prospectus&#148; means each prospectus included in such registration statement (and any amendments thereto) before effectiveness, any prospectus filed with the Commission pursuant to
Rule 424(a) under the Securities Act and the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430 Information (the &#147;Base Prospectus&#148;), and the prospectus supplement thereto dated
September&nbsp;14, 2022 relating to the Shares, and the term &#147;Prospectus&#148; means the Base Prospectus and prospectus supplement in the form first used (or made available upon request of purchasers pursuant to Rule 173 under the Securities
Act) in connection with confirmation of sales of the Shares. If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the &#147;Rule 462 Registration Statement&#148;), then any reference herein
to the term &#147;Registration Statement&#148; shall be deemed to include such Rule 462 Registration Statement. Any reference in this underwriting agreement (this &#147;Agreement&#148;) to the Registration Statement, any Preliminary Prospectus or
the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, as of the effective date of the Registration
Statement or the date of such Preliminary Prospectus or the Prospectus, as the case may be, and any reference to &#147;amend,&#148; &#147;amendment&#148; or &#147;supplement&#148; with respect to the Registration Statement, any Preliminary
Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date under the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the
&#147;Exchange Act&#148;) that are deemed to be incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Registration Statement and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the Applicable Time (as defined below), the Company had prepared the following information (collectively with the pricing
information set forth on Annex A, the &#147;Pricing Disclosure Package&#148;): a Preliminary Prospectus dated September&nbsp;14, 2022 and each &#147;free-writing prospectus&#148; (as defined pursuant to Rule 405 under the Securities Act) listed on
Annex A hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Applicable Time&#148; means 7:20 P.M., New York City time, on September&nbsp;14, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase of the Shares</U>. (a)&nbsp;The Company agrees to issue and sell the Underwritten Shares to the several Underwriters as
provided in this Agreement, and each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per share of
$9.87 (the &#147;Purchase Price&#148;) from the Company the respective number of Underwritten Shares set forth opposite such Underwriter&#146;s name in Schedule 1 hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company agrees to issue and sell the Option Shares to the several Underwriters as provided in this Agreement, and the
Underwriters, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, shall have the option to purchase, severally and not jointly, from the Company the Option
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares at the Purchase Price less an amount per share equal to any dividends or distributions declared by the Company and payable on the Underwritten Shares but not payable on the Option Shares.
If any Option Shares are to be purchased, the number of Option Shares to be purchased by each Underwriter shall be the number of Option Shares which bears the same ratio to the aggregate number of Option Shares being purchased as the number of
Underwritten Shares set forth opposite the name of such Underwriter in Schedule 1 hereto (or such number increased as set forth in Section&nbsp;10 hereof) bears to the aggregate number of Underwritten Shares being purchased from the Company by the
several Underwriters, subject, however, to such adjustments to eliminate any fractional Shares as the Representatives in their sole discretion shall make. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriters may exercise the option to purchase Option Shares at any time in whole, or from time to time in part, on or before the
thirtieth day following the date of the Prospectus, by written notice from the Representatives to the Company. Such notice shall set forth the aggregate number of Option Shares as to which the option is being exercised and the date and time when the
Option Shares are to be delivered and paid for, which may be the same date and time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor later than the tenth full business day (as hereinafter defined) after
the date of such notice (unless such time and date are postponed in accordance with the provisions of Section&nbsp;10 hereof). Any such notice shall be given at least two business days prior to the date and time of delivery specified therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company understands that the Underwriters intend to make a public offering of the Shares, and initially to offer the Shares on the
terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Shares to or through any affiliate of an Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Payment for the Shares shall be made by wire transfer in immediately available funds to the account specified by the Company to the
Representatives in the case of the Underwritten Shares, at the offices of Davis Polk&nbsp;&amp; Wardwell LLP, 1600 El Camino Real, Menlo Park, California 94025 at 10:00 A.M., New York City time, on September&nbsp;19, 2022, or at such other time or
place on the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing or, in the case of the Option Shares, on the date and at the time and place specified by the
Representatives in the written notice of the Underwriters&#146; election to purchase such Option Shares. The time and date of such payment for the Underwritten Shares is referred to herein as the &#147;Closing Date,&#148; and the time and date for
such payment for the Option Shares, if other than the Closing Date, is herein referred to as the &#147;Additional Closing Date.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment for the Shares to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be made against delivery
to the Representatives for the respective accounts of the several Underwriters of the Shares to be purchased on such date or the Additional Closing Date, as the case may be, with any transfer taxes payable in connection with the sale of such Shares
duly paid by the Company. Delivery of the Shares shall be made through the facilities of The Depository Trust Company (&#147;DTC&#148;) unless the Representatives shall otherwise instruct. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company acknowledges and agrees that the Representatives and the other Underwriters
are acting solely in the capacity of an arm&#146;s length contractual counterparty to the Company with respect to the offering of Shares contemplated hereby (including in connection with determining the terms of the offering) and not as a financial
advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally, neither the Representatives nor any other Underwriter is advising the Company or any other person as to any legal, tax, investment, accounting or regulatory
matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither the
Representatives nor any other Underwriter shall have any responsibility or liability to the Company with respect thereto. Any review by the Representatives and the other Underwriters of the Company, the transactions contemplated hereby or other
matters relating to such transactions will be performed solely for the benefit of the Representatives and the other Underwriters and shall not be on behalf of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of the Company</U>. The Company represents and warrants to each Underwriter that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Preliminary Prospectus.</I> No order preventing or suspending the use of any Preliminary Prospectus has been issued by
the Commission, and each Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the Securities Act, and no Preliminary Prospectus, at the time of filing thereof,
contained any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U>, that the Company
makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives
expressly for use in any Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Pricing Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing
Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading; <U>provided</U>, that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to
the Company in writing by such Underwriter through the Representatives expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter consists of the information
described as such in Section&nbsp;7(b) hereof. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that is
required to be included in the Prospectus has been omitted therefrom. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Issuer Free Writing Prospectus. </I>Other than the Registration
Statement, the Preliminary Prospectus and the Prospectus, the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not
prepare, make, use, authorize, approve or refer to any &#147;written communication&#148; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Shares (each such communication by
the Company or its agents and representatives, excluding a communication referred to in clause (i)&nbsp;below, an &#147;Issuer Free Writing Prospectus&#148;) other than (i)&nbsp;any document not constituting a prospectus pursuant to
Section&nbsp;2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act or (ii)&nbsp;the documents listed on Annex A hereto, each electronic road show and any other written communications approved in writing in advance by the
Representatives. Each such Issuer Free Writing Prospectus complied, or will comply, in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities Act (to
the extent required thereby), and, when taken together with the Registration Statement, the Pricing Disclosure Package, all other Issuer Free Writing Prospectuses and the Preliminary Prospectus accompanying, or delivered prior to delivery of, or
filed prior to the first use of, such Issuer Free Writing Prospectus, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a
material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U>, that the Company makes no representation or warranty with respect to any statements or
omissions made in each such Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives
expressly for use in such Issuer Free Writing Prospectus or Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Emerging Growth Company</I>. From the time of initial confidential submission of the Company&#146;s Registration
Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;377-02466)</FONT> to the Commission through the date hereof, the Company has been and is an &#147;emerging growth company,&#148; as defined
in Section&nbsp;2(a) of the Securities Act (an &#147;Emerging Growth Company&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
<I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Materials. </I>The Company (i)&nbsp;has not engaged in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications and (ii)&nbsp;has not authorized anyone to engage in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications (as defined below). <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Testing-the-Waters</FONT></FONT>
Communication&#148; means any oral or written communication with potential investors undertaken in reliance on Section&nbsp;5(d) of, or Rule 163B under, the Securities Act. The Company has not distributed or approved for distribution any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications (as defined below). &#147;Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication&#148; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Registration Statement and Prospectus.</I> The Registration Statement
has been declared effective by the Commission. No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act against the
Company or related to the offering of the Shares has been initiated or, to the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective amendment thereto, the
Registration Statement and any such post-effective amendment complied and will comply in all material respects with the applicable requirements of the Securities Act, and did not and will not contain any untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date and as of the
Additional Closing Date, as the case may be, the Prospectus will comply in all material respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U>, that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in
conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, the Prospectus and any amendment or supplement thereto, it
being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Incorporated Documents</I>. The documents incorporated by reference in the Registration Statement, the Prospectus and
the Pricing Disclosure Package, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of such documents contained any untrue statement of a material fact or omitted to state a
material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and any further documents so filed and incorporated by reference in the Registration Statement, the Prospectus or
the Pricing Disclosure Package, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and will not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Financial Statements.</I> The financial statements (including the related notes thereto) of the Company included or
incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly
in all material respects the financial position of the Company as of the dates indicated and the results of its operations and the changes in its cash flows for the periods specified; such financial statements have been prepared in conformity with
generally accepted accounting principles in the United States (&#147;GAAP&#148;) applied on a consistent basis throughout the periods covered thereby, except in the case </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of unaudited interim financial statements, which are subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and do not contain certain footnotes as permitted by the
applicable rules of the Commission, and any supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects the information required to be stated therein; and the other financial
information included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and presents fairly in all material respects the
information shown thereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>No Material Adverse Change.</I> Since the date of the most recent financial statements
of the Company included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any change in the capital stock (other than the issuance of shares of Common Stock
upon exercise of stock options and warrants described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the Pricing Disclosure Package and the Prospectus),
short-term debt or long-term debt of the Company, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any development that would
reasonably be expected to result in a material adverse change, in or affecting the business, properties, management, financial position, stockholders&#146; equity or results of operations or prospects of the Company; (ii)&nbsp;the Company has not
entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company or incurred any liability or obligation, direct or contingent, that is material to the Company; and (iii)&nbsp;the Company
has not sustained any loss or interference with its business that is material to the Company and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any
action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Organization and Good Standing.</I> The Company has been duly organized and is validly existing and in good standing
under the laws of its jurisdiction of organization, is duly qualified to do business and is in good standing in each jurisdiction in which its ownership or lease of property or the conduct of its businesses requires such qualification, and has all
power and authority necessary to own or hold its properties and to conduct the business in which it is engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the
aggregate, have a material adverse effect on the business, properties, management, financial position, stockholders&#146; equity, results of operations or prospects of the Company or on the performance by the Company of its obligations under this
Agreement (a &#147;Material Adverse Effect&#148;). The Company does not have any subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Capitalization.</I>
The Company has an authorized capitalization as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Capitalization&#148;; all the outstanding shares of capital stock of the Company have
been duly and validly authorized and issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
and are not subject to any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights; except as described in or expressly contemplated by the Pricing Disclosure Package and the
Prospectus, there are no outstanding rights (including, without limitation, <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock
or other equity interest in the Company, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company, any such convertible or exchangeable securities or any such
rights, warrants or options; the capital stock of the Company conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Stock Options. </I>With respect to the stock options (the &#147;Stock Options&#148;) granted pursuant to the stock-based
compensation plans of the Company (the &#147;Company Stock Plans&#148;), (i) each Stock Option intended to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the
&#147;Code&#148;), so qualifies, (ii)&nbsp;each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective (the &#147;Grant Date&#148;) by all necessary corporate
action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award
agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii)&nbsp;each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and all applicable laws and regulatory rules
or requirements, including the rules of the Nasdaq Global Select Market (the &#147;Nasdaq Market&#148;) and any other exchange on which Company securities are traded, and (iv)&nbsp;each such grant was properly accounted for in accordance with GAAP
in the financial statements (including the related notes) of the Company and disclosed in the Company&#146;s filings with the Commission in accordance with the Exchange Act and all other applicable laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Due Authorization.</I> The Company has full right, power and authority to execute and deliver this Agreement and to
perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly
taken. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Underwriting Agreement</I>. This Agreement has been duly authorized, executed and delivered by the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>The Shares.</I> The Shares to be issued and sold by the Company hereunder have been duly authorized by the Company
and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform to the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and the
Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>No Violation or Default.</I> The Company is not (i)&nbsp;in violation
of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due
performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company is a party or by which the Company is bound or to which any
property or asset of the Company is subject; or (iii)&nbsp;in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii)&nbsp;and
(iii) above, for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>No Conflicts. </I>The execution, delivery and performance by the Company of this Agreement, the issuance and sale of the
Shares by the Company and the consummation by the Company of the transactions contemplated by this Agreement or the Pricing Disclosure Package and the Prospectus will not (i)&nbsp;conflict with or result in a breach or violation of any of the terms
or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset of the Company pursuant to, any
indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company is a party or by which the Company is bound or to which any property, right or asset of the Company is subject, (ii)&nbsp;result in any
violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents of the Company or (iii)&nbsp;result in the violation of any law or statute or any judgment, order, rule or regulation
of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i)&nbsp;and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the
aggregate, have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <I>No Consents Required.</I> No consent, approval, authorization, order,
registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale by the Company of the Shares and
the consummation of the transactions contemplated by this Agreement, except for the registration of the Shares under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as have already been
obtained or made or as may be required by the Financial Industry Regulatory Authority, Inc. (&#147;FINRA&#148;), the Nasdaq Market and under applicable state securities laws in connection with the purchase and distribution of the Shares by the
Underwriters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <I>Legal Proceedings.</I> Except as described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (&#147;Actions&#148;) pending to which the Company is or may reasonably be expected to
become a party or to which any property of the Company is or may reasonably be expected to become the subject that, individually or in the aggregate, if determined adversely to the Company, would reasonably be expected to have a Material
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Adverse Effect; to the knowledge of the Company, no such Actions are threatened or contemplated by any governmental or regulatory authority or threatened by others; and (i)&nbsp;there are no
current or pending Actions that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus and (ii)&nbsp;there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the Registration Statement,
the Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <I>Independent Accountants</I>. PricewaterhouseCoopers LLP, who has certified certain financial statements of the Company,
is an independent registered public accounting firm with respect to the Company within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities
Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <I>Title to Real and Personal Property.</I> The Company has good and marketable title in fee simple (in the case
of real property) to, or has valid rights to lease or otherwise use, all items of real and personal property that are material to the business of the Company, in each case free and clear of all liens, encumbrances, claims and defects and
imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to be made of such property by the Company or (ii)&nbsp;could not reasonably be expected, individually or in the aggregate, to have a
Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Intellectual Property.</I> Except as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus (i)&nbsp;to the knowledge of the Company, the Company owns or has the right to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations,
domain names and other source indicators, copyrights, copyright registrations, copyrightable works, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, systems, procedures, proprietary or confidential information and all other
intellectual property and proprietary and similar rights and all goodwill associated with any of the foregoing (collectively, &#147;Intellectual Property&#148;) in each case necessary for the conduct of its business in the manner described in the
Registration Statement, the Pricing Disclosure Package and the Prospectus; (ii)&nbsp;to the knowledge of the Company, the conduct of the Company&#146;s business as described in the Registration Statement, Pricing Disclosure Package and Prospectus
has not infringed, misappropriated or otherwise violated, and does not and will not infringe, misappropriate or otherwise violate any Intellectual Property of any third party in any material respect; (iii)&nbsp;there is no pending or, to the
knowledge of the Company, threatened action, suit, proceeding or claim by any third party (x)&nbsp;challenging the Company&#146;s rights in or to, or alleging violation of any terms of, any of its owned or licensed Intellectual Property,
(y)&nbsp;alleging that the Company has infringed, misappropriated or otherwise violated the Intellectual Property Rights of any third party or (z)&nbsp;challenging the ownership, validity, scope or enforceability of any Intellectual Property owned
by or licensed to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company, and in the case of (x), (y) and (z)&nbsp;the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; and (iv)&nbsp;to the
knowledge of the Company, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, all Intellectual Property owned by or licensed to the Company is valid and enforceable, is owned free and
clear of all liens, encumbrances, defects and other restrictions by, or licensed or <FONT STYLE="white-space:nowrap">co-licensed</FONT> to, the Company, and no third party has infringed, misappropriated or otherwise violated any Intellectual
Property owned by or exclusively or <FONT STYLE="white-space:nowrap">co-exclusively</FONT> licensed to the Company. Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, the Company has at
all times taken reasonable steps in accordance with normal industry practice to maintain the confidentiality of all Intellectual Property, the value of which to the Company is contingent upon maintaining the confidentiality thereof, including the
execution of appropriate nondisclosure and confidentiality agreements, and, to the knowledge of the Company, no such Intellectual Property has been disclosed except pursuant to such agreements. All parties involved in the development of Intellectual
Property for the Company have signed agreements with the Company, pursuant to which the Company either (A)&nbsp;has obtained ownership of and is the exclusive owner of such Intellectual Property, or (B)&nbsp;has obtained a valid right to exploit
such Intellectual Property, sufficient for the conduct of its business as currently conducted or as proposed to be conducted in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <I>No Undisclosed Relationships.</I> No relationship, direct or indirect, exists between or among the Company, on the one
hand, and the directors, officers, stockholders, customers or suppliers or other affiliates of the Company, on the other, that is required by the Securities Act to be described in each of the Registration Statement and the Prospectus and that is not
so described in such documents and in the Pricing Disclosure Package. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <I>Investment Company Act.</I> The Company is
not and, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an
&#147;investment company&#148; or an entity &#147;controlled&#148; by an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively,
the &#147;Investment Company Act&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <I>Taxes.</I> The Company has filed all U.S. federal, state, local and
foreign tax returns required to be filed, and has paid all U.S. federal, state, local and foreign taxes required to be paid through the date hereof, except in each case, as would not be expected to result in a Material Adverse Effect; and except as
would not be expected to result in a Material Adverse Effect, there is no tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any of its properties or assets. The charges, accruals and reserves on the
books of the Company in respect of any income and corporation tax liability for any years not finally determined are, in conformity with GAAP, adequate to meet any assessments or <FONT STYLE="white-space:nowrap">re-assessments</FONT> for additional
income tax for any years not finally determined, except to the extent of any inadequacies that would not result in a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <I>Licenses and Permits.</I> The Company possesses all licenses, <FONT
STYLE="white-space:nowrap">sub-licenses,</FONT> certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that
are necessary for the ownership or lease of its properties or the conduct of its business as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, including, without limitation, from the U.S. Food and
Drug Administration (&#147;FDA&#148;), except where the failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse Effect; and the Company has not received notice of any revocation or modification of any
such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit, approval, clearance or authorization or has any reason to believe that any such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit
or authorization will not be renewed in the ordinary course, except where the occurrence of such an event, individually or in the aggregate, would not have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <I>No Labor Disputes.</I> No labor disturbance by or dispute with employees of the Company exists or, to the knowledge of
the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its principal suppliers, contractors or customers, except as would not have a
Material Adverse Effect. The Company is not party to any collective bargaining agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <I>Certain Environmental
Matters</I>. (i)&nbsp;The Company (x)&nbsp;is in compliance with all, and has not violated any, applicable federal, state, local and foreign laws, rules, regulations, requirements, decisions, judgments, decrees and orders relating to pollution or
the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#147;Environmental Laws&#148;); (y) has received and is in compliance with all, and has
not violated any, permits, licenses, certificates or other authorizations or approvals required of it under any Environmental Laws to conduct its business; and (z)&nbsp;has not received notice of any actual or potential liability of the Company, or
obligation of the Company, under or relating to, or any actual or potential violation of, any Environmental Laws by the Company, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes,
pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;there are no costs or liabilities associated with Environmental Laws of or relating to the Company,
except in the case of each of (i)&nbsp;and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii)&nbsp;(x) there is no proceeding that is pending, or that
is known by the Company to be contemplated, against the Company under any Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding which the Company reasonably believes no monetary sanctions of $100,000
or more will be imposed, (y)&nbsp;the Company is not aware of any facts regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or
contaminants, that would reasonably be expected to have a Material Adverse Effect, and (z)&nbsp;the Company does not anticipate material capital expenditures relating to any Environmental Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <I>Compliance with ERISA</I>. (i)&nbsp;Each employee benefit plan,
within the meaning of Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#147;ERISA&#148;), for which the Company or any member of its &#147;Controlled Group&#148; (defined as any entity, whether or not
incorporated, that is under common control with the Company within the meaning of Section&nbsp;4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b), (c), (m) or (o)&nbsp;of the
Code) would have any liability (each, a &#147;Plan&#148;) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii)&nbsp;no
prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii)&nbsp;for each
Plan that is subject to the funding rules of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of
Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code) applicable to such Plan; (iv)&nbsp;no Plan is, or is reasonably expected to be, in &#147;at risk status&#148; (within the meaning of Section&nbsp;303(i) of ERISA) and no Plan that is a
&#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA is in &#147;endangered status&#148; or &#147;critical status&#148; (within the meaning of Sections 304 and 305 of ERISA)&nbsp;(v) the fair market value of the
assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no &#147;reportable event&#148; (within the meaning of Section&nbsp;4043(c) of ERISA and the
regulations promulgated thereunder) has occurred or is reasonably expected to occur; (vii)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified, and nothing has occurred, whether by action or by
failure to act, which would cause the loss of such qualification; (viii)&nbsp;neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions
to the Plan or premiums to the Pension Benefit Guarantee Corporation, in the ordinary course and without default) in respect of a Plan (including a &#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA); and
(ix)&nbsp;none of the following events has occurred or is reasonably likely to occur: (A)&nbsp;a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the
current fiscal year of the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company&#146;s and its Controlled Group affiliates&#146; most recently completed fiscal year; or (B)&nbsp;a material
increase in the Company&#146;s &#147;accumulated post-retirement benefit obligations&#148; (within the meaning of Accounting Standards Codification Topic <FONT STYLE="white-space:nowrap">715-60)</FONT> compared to the amount of such obligations in
the Company&#146;s most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i)&nbsp;through (ix) hereof, as would not, individually or in the aggregate, have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <I>Disclosure Controls</I>. The Company maintains an effective system
of &#147;disclosure controls and procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that has been designed to comply with the applicable requirements of the Exchange Act and designed to ensure
that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#146;s rules and forms, including
controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required disclosure. The Company has carried out an evaluation of
its disclosure controls and procedures as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <I>Accounting Controls.</I> The Company maintains systems of &#147;internal control over financial reporting&#148; (as
defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) designed to comply with the applicable requirements of the Exchange Act and that have been designed by, or under the supervision of, its principal executive and
principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP,
including internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated
by reference in the Registration Statement fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. There are no material weaknesses in the
Company&#146;s internal controls. The Company&#146;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i)&nbsp;all significant deficiencies and material weaknesses, if any, in the design or operation of
internal controls over financial reporting which have adversely affected or are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial information; and (ii)&nbsp;any fraud, whether or not
material, that involves management or other employees who have a significant role in the Company&#146;s internal controls over financial reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <I>Insurance.</I> The Company has insurance covering its properties, operations, personnel and businesses, including
business interruption insurance, which insurance is in amounts and insures against such losses and risks as are generally maintained by similarly situated companies and which the Company reasonably believes are adequate to protect the Company and
its business; and the Company (i)&nbsp;has not received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance and (ii)&nbsp;has no
reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <I>Cybersecurity; Data Protection. </I>The information technology
assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases owned by the Company (collectively, &#147;IT Systems&#148;), to the knowledge of the Company, are adequate for, and operate and perform in
all material respects as required in connection with the operation of the business of the Company as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company has
implemented and maintained commercially reasonable policies and procedures to maintain its material personal data (&#147;Personal Data&#148;) and confidential information and the integrity, continuous operation, redundancy and security of all IT
Systems used in connection with its business, and, to the knowledge of the Company, there have been no breaches, violations or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or
the duty to notify any other person. The Company is presently in material compliance with all applicable laws, statutes, judgments, orders, and regulations of any governmental or regulatory authority and, to the Company&#146;s knowledge, all
internal policies and contractual obligations, in each case relating to the privacy and security of IT Systems and Personal Data, including, but not limited to, to the extent applicable, the General Data Protection Regulation (EU) 2016/679 and the
California Consumer Privacy Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <I>No Unlawful Payments.</I> Neither the Company, nor any director, officer or
employee of the Company nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company has (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other
unlawful expense relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee,
including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for
political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials
in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, agreed, requested or taken an act in
furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Company has instituted, maintain and enforce, and will
continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Compliance with Anti-Money Laundering Laws</I>. The operations of
the Company are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money
laundering statutes of all jurisdictions where the Company conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively,
the &#147;Anti-Money Laundering Laws&#148;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Anti-Money Laundering Laws is pending or, to
the knowledge of the Company, threatened. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <I>No Conflicts with Sanctions Laws. </I>Neither the Company nor any of its
directors, officers or employees, nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company is currently the subject or the target of any sanctions administered or enforced by the
U.S. government (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation as a &#147;specially designated
national&#148; or &#147;blocked person&#148;), the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury or other relevant sanctions authority (collectively, &#147;Sanctions&#148;), nor is the Company located, organized or
resident in a country or territory that is the subject or target of Sanctions, including, without limitation, Cuba, Iran, North Korea, Syria, the Crimea Region of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s
Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic and any other Covered Region of Ukraine identified pursuant to Executive Order 14065 (each, a &#147;Sanctioned Country&#148;); and the Company will not
directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any
activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii)&nbsp;to fund or facilitate any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other
manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. Since incorporation, the Company has not knowingly engaged in and is
not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <I>No Broker&#146;s Fees.</I> The Company is not a party to any contract, agreement or understanding with any person
(other than this Agreement) that would give rise to a valid claim against the Company or any Underwriter for a brokerage commission, finder&#146;s fee or like payment in connection with the offering and sale of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <I>No Registration Rights</I>. No person has the right to require the Company to register any securities for sale under
the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Shares by the Company hereunder, other than those rights that have been validly waived. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <I>No Stabilization.</I> Neither the Company, nor, to the Company&#146;s knowledge, its affiliates have taken, directly or
indirectly, without giving effect to activities by the Underwriters, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <I>Margin Rules</I>. Neither the issuance, sale and delivery of the
Shares by the Company nor the application of the proceeds thereof by the Company as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will not violate Regulation T, U or X of the Board of Governors of
the Federal Reserve System or any other regulation of such Board of Governors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <I>Forward-Looking Statements.</I> No
forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the
Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp)
<I>Statistical and Market Data.</I> Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included or incorporated by reference in each of the Registration Statement, the
Pricing Disclosure Package and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <I>Clinical Trials. </I>The clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> trials conducted by or on
behalf of or sponsored by the Company, or in which the Company has participated, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or the results of which are referred to in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, as applicable, were, and if still pending are, being conducted in all material respects in accordance with standard medical and scientific research standards and procedures and all
applicable statutes, including the Federal Food, Drug, and Cosmetic Act, and all applicable rules and regulations of the FDA and other applicable regulatory authorities (including, without limitation, any foreign, federal, state or local
governmental or regulatory authority performing functions similar to those performed by the FDA) (collectively, the &#147;Regulatory Authorities&#148;) and current Good Clinical Practices and Good Laboratory Practices; the descriptions in the
Registration Statement, the Pricing Disclosure Package and the Prospectus of the results of such studies and tests are accurate and complete in all material respects and fairly present the data derived from such trials; the Company has no knowledge
of any other trials, the results of which are inconsistent with or call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package or the Prospectus; the Company has operated at all times and is
currently in compliance in all material respects with all applicable statutes, rules and regulations of the Regulatory Authorities; and the Company has not received any written notices, correspondence or other communications from the Regulatory
Authorities or any other governmental agency requiring or threatening the termination, material modification or suspension of any clinical or <FONT STYLE="white-space:nowrap">pre-clinical</FONT> trials that are described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, and, to the knowledge of the Company, there are no reasonable
grounds for the same. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <I>Regulatory Filings.</I> The Company has not failed to file with the
applicable Regulatory Authorities any material required filing, declaration, listing, registration, report or submission; all such filings, declarations, listings, registrations, reports or submissions were in material compliance with applicable
laws when filed; and no material deficiencies have been asserted by any applicable Regulatory Authority with respect to any such filings, declarations, listings, registrations, reports or submissions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <I>Sarbanes-Oxley Act</I>. There is and has been no failure on the part of the Company or any of the Company&#146;s
directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated in connection therewith (the &#147;Sarbanes-Oxley Act&#148;),
including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <I>Status under the
Securities Act</I>. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the meaning of Rule
164(h)(2) under the Securities Act) of the Shares and at the date hereof, the Company was not and is not an &#147;ineligible issuer,&#148; as defined in Rule 405 under the Securities Act. The Company has paid the registration fee for this offering
pursuant to Rule 456(b)(1) under the Securities Act or will pay such fee within the time period required by such rule (without giving effect to the proviso therein) and in any event prior to the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) <I>No Ratings</I>. There are (and prior to the Closing Date, will be) no debt securities, convertible securities or
preferred stock issued or guaranteed by the Company that are rated by a &#147;nationally recognized statistical rating organization,&#148; as such term is defined in Section&nbsp;3(a)(62) under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Further Agreements of the Company</U>. The Company covenants and agrees with each Underwriter that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Required Filings.</I> The Company will file the final Prospectus with the Commission within the time periods specified
by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, and will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; and the Company will file promptly all reports and any definitive
proxy or information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus
is required in connection with the offering or sale of the Shares; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the Underwriters in New York City prior to
10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representatives may reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Delivery of Copies.</I> The Company will deliver, upon request and
without charge, (i)&nbsp;to the Representatives, four signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by
reference therein; and (ii)&nbsp;to each Underwriter (A)&nbsp;a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as
many copies of the Prospectus (including all amendments and supplements thereto and documents incorporated by reference therein and each Issuer Free Writing Prospectus) as the Representatives may reasonably request. As used herein, the term
&#147;Prospectus Delivery Period&#148; means such period of time after the first date of the public offering of the Shares as in the opinion of counsel for the Underwriters a prospectus relating to the Shares is required by law to be delivered (or
required to be delivered but for Rule 172 under the Securities Act) in connection with sales of the Shares by any Underwriter or dealer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Amendments or Supplements, Issuer Free Writing Prospectuses.</I> Before making, preparing, using, authorizing,
approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company will furnish to the Representatives and
counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not make, prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such
proposed amendment or supplement to which the Representatives reasonably object. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Notice to the Representatives.</I>
The Company will advise the Representatives promptly, and confirm such advice in writing (which may be by electronic mail), (i) when the Registration Statement has become effective; (ii)&nbsp;when any amendment to the Registration Statement has been
filed or becomes effective; (iii)&nbsp;when any supplement to the Pricing Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus or any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or any amendment to the Prospectus has been filed or distributed; (iv)&nbsp;of any request by the Commission for any amendment to the
Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional information including, but
not limited to, any request for information concerning any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication; (v)&nbsp;of the issuance by the Commission of any order suspending the
effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package, the Prospectus or any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or the initiation or, to the knowledge of the Company, threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of
the Securities Act; (vi)&nbsp;of the occurrence of any event or development within the Prospectus Delivery Period as a result of which the Prospectus, the Pricing Disclosure Package, any Issuer Free Writing Prospectus or any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package, any such Issuer Free Writing Prospectus or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication is delivered to a purchaser, not misleading; and (vii)&nbsp;of the
receipt by the Company of any notice with respect to any suspension of the qualification of the Shares for offer and sale in any jurisdiction or the initiation or, to the knowledge of the Company, threatening of any proceeding for such purpose; and
the Company will use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure
Package or the Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or suspending any such qualification of the Shares and, if any such order is issued, will
obtain as soon as possible the withdrawal thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Ongoing Compliance.</I> (1)&nbsp;If during the Prospectus
Delivery Period (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Prospectus to comply with law, the
Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments
or supplements to the Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or supplemented (or any document to be filed with the
Commission and incorporated by reference therein) will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2)&nbsp;if at any time prior to
the Closing Date or any Additional Closing Date, as the case may be, (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue
statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or
(ii)&nbsp;it is necessary to amend or supplement the Pricing Disclosure Package to comply with law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission
(to the extent required) and furnish to the Underwriters and to such dealers as the Representatives may designate, such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with the Commission and incorporated by
reference therein) as may be necessary so that the statements in the Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be
misleading or so that the Pricing Disclosure Package will comply with law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Blue Sky Compliance.</I> The Company
will qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for distribution of the
Shares; <U>provided</U>, that the Company shall not be required to (i) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general consent
to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Earnings Statement. </I>The Company will make generally available to its security holders and the Representatives as
soon as practicable an earnings statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal
quarter of the Company occurring after the &#147;effective date&#148; (as defined in Rule 158) of the Registration Statement; <U>provided</U>, that the Company will be deemed to have furnished such earnings statements to its security holders and the
Representatives to the extent they are filed on the Commission&#146;s Electronic Data Gathering, Analysis and Retrieval system (&#147;EDGAR&#148;) or any successor system, and satisfies the provisions of Section&nbsp;11(a) of the Securities Act and
Rule 158 of the Commission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Clear Market.</I> For a period of 60 days after the date of the Prospectus (the
&#147;Restricted Period&#148;), the Company will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise
transfer or dispose of, directly or indirectly, or submit to, or file with, the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible into or exercisable or exchangeable for
Stock, or publicly disclose the intention to undertake any of the foregoing, or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other
securities, whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of the Representatives, other than
(A)&nbsp;the Shares to be sold hereunder, (B)&nbsp;any shares of Stock or other securities of the Company issued upon the exercise, vesting or settlement of options or other awards granted under Company Stock Plans or other equity incentive plan or
stock purchase plan (collectively, &#147;Equity Plans&#148;) in effect on the date hereof and that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, under the terms of such plan, (C)&nbsp;any options and
other awards granted or issued under an Equity Plan in effect on the date hereof and described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, under the terms of such plan, (D)&nbsp;the filing by the Company of any
registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto relating to an Equity Plan in effect on the date hereof and described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus and (E)&nbsp;the issuance of securities by the Company in connection with mergers, acquisitions or commercial or strategic transactions, provided that the aggregate number of shares issued pursuant to this clause (E)&nbsp;does not exceed
5% of the Company&#146;s securities outstanding immediately following the issuance and sale of the Shares pursuant hereto; provided, that the recipient of any such shares of Stock or securities issued pursuant to clauses (B)&nbsp;and (E) during the
Restricted Period shall enter into an agreement for the remainder of the Restricted Period substantially in the form of Exhibit A hereto. The Company may only be released from the foregoing restrictions with the prior written consent of the
Representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Use of Proceeds.</I> The Company will apply the net proceeds from the
sale of the Shares as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Use of proceeds.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>No Stabilization.</I> The Company will not take, directly or indirectly, without giving effect to activities by the
Underwriters, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Exchange Listing</I>. The Company will use its reasonable best efforts to list for quotation the Shares on the Nasdaq
Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Reports.</I> During a period of three years from the date of this Agreement, the Company will furnish to
the Representatives, as soon as commercially reasonable after the date that they are available, copies of all reports or other communications (financial or other) furnished to holders of the Shares, and copies of any reports and financial statements
furnished to or filed with the Commission or any national securities exchange or automatic quotation system; <I>provided</I> the Company will be deemed to have furnished such reports and financial statements to the Representatives to the extent they
are filed on EDGAR or any successor system. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Record Retention</I>. The Company will, pursuant to reasonable
procedures developed in good faith, retain copies of each Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Filings.</I> The Company will file with the Commission such reports as may be required by Rule 463 under the Securities
Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>Emerging Growth Company</I>. The Company will promptly notify the Representatives if the Company ceases to be
an Emerging Growth Company at any time prior to the later of (i)&nbsp;completion of the distribution of Shares within the meaning of the Securities Act and (ii)&nbsp;completion of the Restricted Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>Shelf Renewal.</I> If immediately prior to the third anniversary (the &#147;Renewal Deadline&#148;) of the initial
effective date of the Registration Statement, any of the Shares remain unsold by the Underwriters, the Company will, prior to the Renewal Deadline, file, if it has not already done so and is eligible to do so, a new automatic shelf registration
statement relating to the Shares, in a form satisfactory to the Representatives. If the Company is not eligible to file an automatic shelf registration statement, the Company will, prior to the Renewal Deadline, if it has not already done so, file a
new shelf registration statement relating to the Shares, in a form satisfactory to the Representatives, and will use its best efforts to cause such registration statement to be declared effective within 180 days after the Renewal Deadline. The
Company will take all other action necessary or appropriate to permit the issuance and sale of the Shares to continue as contemplated in the expired registration statement relating to the Shares. References herein to the Registration Statement shall
include such new automatic shelf registration statement or such new shelf registration statement, as the case may be.<I> </I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Certain Agreements of the Underwriters</U>. Each Underwriter hereby severally
represents and agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) It has not, and will not, use, authorize use of, refer to or participate in the planning
for use of, any &#147;free writing prospectus,&#148; as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into the
Registration Statement and any press release issued by the Company) other than (i)&nbsp;a free writing prospectus that contains no &#147;issuer information&#148; (as defined in Rule 433(h)(2) under the Securities Act) that was not included
(including through incorporation by reference) in the Preliminary Prospectus or a previously filed Issuer Free Writing Prospectus, (ii)&nbsp;any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section&nbsp;3(c) or
Section&nbsp;4(c) above (including any electronic road show), or (iii)&nbsp;any free writing prospectus prepared by such underwriter and approved by the Company in advance in writing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It has not and will not, without the prior written consent of the Company, use any free writing prospectus that contains
the final terms of the Shares unless such terms have previously been included in a free writing prospectus filed with the Commission; <U>provided</U>, that Underwriters may use a term sheet substantially in the form of Annex B hereto without the
consent of the Company; <U>provided further</U>, that any Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company, prior to, or substantially concurrent with, the first use of such term sheet.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) It is not subject to any pending proceeding under Section&nbsp;8A of the Securities Act with respect to the offering
(and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.
<U>Conditions of Underwriters&#146; Obligations.</U> The obligation of each Underwriter to purchase the Underwritten Shares on the Closing Date or the Option Shares on the Additional Closing Date, as the case may be, as provided herein is subject to
the performance by the Company of its respective covenants and other obligations hereunder and to the following additional conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Registration Compliance; No Stop Order.</I> No order suspending the effectiveness of the Registration Statement shall be
in effect, and no proceeding for such purpose or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with
the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section&nbsp;4(a) hereof; and all requests by the Commission for
additional information shall have been complied with to the reasonable satisfaction of the Representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Representations and Warranties.</I> The representations and
warranties of the Company contained herein shall be true and correct on the date hereof and on and as of the Closing Date or the Additional Closing Date, as the case may be; and the statements of the Company and its officers made in any certificates
delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date or the Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>No Material Adverse Change.</I> No event or condition of a type described in Section&nbsp;3(i) hereof shall have
occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the
judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by
this Agreement, the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Officer&#146;s Certificate.</I> The
Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer
of the Company who is satisfactory to the Representatives (i)&nbsp;confirming that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the
representations of the Company set forth in Sections 3(b) and 3(f) hereof are true and correct, (ii)&nbsp;confirming that the other representations and warranties of the Company in this Agreement are true and correct and that the Company has
complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or the Additional Closing Date, as the case may be, and (iii)&nbsp;to the effect set forth in paragraphs
(a)&nbsp;and (c) above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Comfort Letters.</I> On the date of this Agreement and on the Closing Date or the
Additional Closing Date, as the case may be, PricewaterhouseCoopers LLP shall have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Representatives, in form
and substance reasonably satisfactory to the Representatives, containing statements and information of the type customarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and
certain financial information contained or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that the letter delivered on the Closing Date or the Additional Closing Date, as
the case may be, shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off&#148;</FONT> date no more than two business days prior to such Closing Date or such Additional Closing Date, as the case may be. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Opinion of Intellectual Property Counsel for the Company.</I> Goodwin
Procter LLP, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. and Lathrop GPM LLP, intellectual property counsel for the Company, shall each have furnished to the Representatives, at the request of the Company, their written opinions, dated the
Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Company.</I> Latham&nbsp;&amp;
Watkins, LLP, counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, dated the Closing Date or the Additional Closing
Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Underwriters.</I> The
Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, an opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, addressed to the Underwriters, of Davis Polk&nbsp;&amp;
Wardwell LLP, counsel for the Underwriters, with respect to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon
such matters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>No Legal Impediment to Issuance and/or Sale.</I> No action shall have been taken and no statute,
rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or
sale of the Shares by the Company; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the
Shares by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Good Standing</I>. The Representatives shall have received on and as of the Closing Date or
the Additional Closing Date, as the case may be, satisfactory evidence of the good standing of the Company in its jurisdiction of organization and its good standing in such other jurisdictions as the Representatives may reasonably request, in each
case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Exchange Listing.</I> The Shares to be delivered on the Closing Date or the Additional Closing Date, as the case may be,
shall have been approved for listing on the Nasdaq Market, subject to official notice of issuance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I><FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. The <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, each substantially in the form of Exhibit A hereto, between you and certain stockholders, officers and directors of
the Company relating to sales and certain other dispositions of shares of Stock or certain other securities, delivered to you on or before the date hereof, shall be in full force and effect on the Closing Date or the Additional Closing Date, as the
case may be. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Additional Documents.</I> On or prior to the Closing Date or the Additional Closing Date, as the case
may be, the Company shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters, certificates and evidence mentioned above or elsewhere in this
Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Indemnification and Contribution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of the Underwriters by the Company.</I> The Company agrees to indemnify and hold harmless each Underwriter, its
affiliates, employees, agents, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, from and against any and all losses,
claims, damages and liabilities (including, without limitation, legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that arise out
of, or are based upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained or incorporated by reference in the Registration Statement or caused by any omission or alleged omission to state therein a material fact
required to be stated therein or necessary in order to make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained or incorporated by reference in the Prospectus (or any
amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any road show as defined in Rule 433(h) under the Securities Act (a &#147;road show&#148;) or any Pricing Disclosure Package (including any
Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the circumstances under which they were
made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with
any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter
consists of the information described as such in subsection (b)&nbsp;below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification of the Company.</I> Each Underwriter
agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the
Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue
statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for
use in the Registration Statement, the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any road show or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being
understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter under the caption &#147;Underwriting&#148;: the third paragraph
concerning the terms of the offering by the Underwriters and the thirteenth and fourteenth paragraphs concerning stabilization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-26- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Notice and Procedures.</I> If any suit, action, proceeding (including any
governmental or regulatory investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section&nbsp;7, such person (the
&#147;Indemnified Person&#148;) shall promptly notify the person against whom such indemnification may be sought (the &#147;Indemnifying Person&#148;) in writing; <U>provided</U> that the failure to notify the Indemnifying Person shall not relieve
it from any liability that it may have under the preceding paragraphs of this Section&nbsp;7 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and <U>provided,
further,</U> that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section&nbsp;7. If any such proceeding shall be
brought or asserted against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the
Indemnified Person, be counsel to the Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate in such proceeding and shall pay the
reasonable fees and expenses in such proceeding and shall pay the reasonable fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel,
but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying Person has failed
within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition
to those available to the Indemnifying Person; or (iv)&nbsp;the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same
counsel would be inappropriate due to actual or potential differing interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be
liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for any
Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall be designated in writing by J.P. Morgan Securities LLC and any such separate firm for the Company, its directors, its officers who signed the
Registration Statement and any control persons of the Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with
such consent, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested
that an Indemnifying Person reimburse the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-27- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Indemnified Person for fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written
consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request
prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been
a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified
Person, from all liability on claims that are the subject matter of such proceeding and (y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Contribution.</I> If the indemnification provided for in paragraphs (a)&nbsp;and (b) above is unavailable to an Indemnified Person or
insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable
by such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters on the other, from
the offering of the Shares or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;but also the
relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations.
The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company from the sale of the
Shares and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate offering price of the Shares. The relative
fault of the Company, on the one hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a
material fact relates to information supplied by the Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Limitation on Liability.</I> The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to
paragraph (d)&nbsp;above were determined by <U>pro</U> <U>rata</U> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations
referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d)&nbsp;above shall be deemed to include, subject to the limitations
set forth above, any legal or other expenses reasonably incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of paragraphs (d)&nbsp;and (e), in no event shall an Underwriter be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-28- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Shares exceeds
the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of
Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute pursuant to paragraphs (d)&nbsp;and (e) are several
in proportion to their respective purchase obligations hereunder and not joint. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
<I><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedies.</I> The remedies provided for in this Section&nbsp;7 paragraphs (a)&nbsp;through (e) are not exclusive and shall not limit any rights or remedies which may otherwise be available to
any Indemnified Person at law or in equity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Effectiveness of Agreement</U>. This Agreement shall become effective as of the date
first written above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Representatives, by notice
to the Company, if after the execution and delivery of this Agreement and on or prior to the Closing Date or, in the case of the Option Shares, prior to the Additional Closing Date (i)&nbsp;trading generally shall have been suspended or materially
limited on or by any of the New York Stock Exchange or The Nasdaq Stock Market; (ii)&nbsp;trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or (iv)&nbsp;there shall have occurred any outbreak
or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and adverse and makes it impracticable or inadvisable to
proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Defaulting Underwriter</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If, on the Closing Date or the Additional Closing Date, as the case may be, any Underwriter defaults on its obligation to purchase the
Shares that it has agreed to purchase hereunder on such date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters may in their discretion arrange for the purchase of such Shares by other persons satisfactory to the Company on the
terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not arrange for the purchase of such Shares, then the Company shall be
entitled to a further period of 36 hours within which to procure other persons satisfactory to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase such Shares on such terms. If other persons become obligated or agree
to purchase the Shares of a defaulting Underwriter, either the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or the Company may postpone the Closing Date or the Additional Closing Date, as the case may be, for up to five full
business days in order to effect any changes that in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-29- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company agrees to promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term
&#147;Underwriter&#148; includes, for all purposes of this Agreement unless the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section&nbsp;10, purchases Shares that a defaulting Underwriter agreed but
failed to purchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or
Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing
Date, as the case may be, does not exceed <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of Shares to be purchased on such date, then the Company shall have the right to require each
<FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase the number of Shares that such Underwriter agreed to purchase hereunder on such date plus such Underwriter&#146;s pro rata share (based on the number of Shares that such
Underwriter agreed to purchase on such date) of the Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be,
exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate amount of Shares to be purchased on such date, or if the Company shall not exercise the right described in paragraph (b)&nbsp;above, then this Agreement or, with respect
to any Additional Closing Date, the obligation of the Underwriters to purchase Shares on the Additional Closing Date, as the case may be, shall terminate without liability on the part of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT>
Underwriters. Any termination of this Agreement pursuant to this Section&nbsp;10 shall be without liability on the part of the Company, except that the Company will continue to be liable for the payment of expenses as set forth in Section&nbsp;11
hereof and except that the provisions of Section&nbsp;7 hereof shall not terminate and shall remain in effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Nothing contained
herein shall relieve a defaulting Underwriter of any liability it may have to the Company or any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages caused by its default. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Payment of Expenses</U><I>.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will pay or
cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the Shares and any taxes
payable in that connection, including any stock or other transfer taxes and any stamp or other duties payable upon the sale, issuance or delivery of the Shares to the Underwriters pursuant to this Agreement; (ii)&nbsp;the costs incident to the
preparation, printing and filing under the Securities Act of the Registration Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing Disclosure Package and the Prospectus (including all exhibits, amendments and
supplements thereto) and the distribution thereof; (iii)&nbsp;the fees and expenses of the Company&#146;s counsel and independent accountants; (iv)&nbsp;the fees and expenses incurred in connection with the registration or qualification and
determination of eligibility for investment of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-30- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Shares under the state or foreign securities or blue sky laws of such jurisdictions as the Representatives may designate and the preparation, printing and distribution of a Blue Sky
Memorandum (including the related fees and reasonable expenses of counsel for the Underwriters);&nbsp;(v) the cost of preparing stock certificates; (vi)&nbsp;the costs and charges of any transfer agent and any registrar; (vii)&nbsp;all expenses and
application fees incurred in connection with any filing with, and clearance of the offering by, FINRA, provided that the aggregate amount payable by the Company pursuant to clauses (iv)&nbsp;and (vii) shall not exceed $25,000 (excluding filing
fees); (viii) all expenses incurred by the Company in connection with any &#147;road show&#148; presentation to potential investors (provided, however, that the Underwriters and the Company shall each pay 50% of the cost of chartering any aircraft
to be used in connection with the road show by the Company and the Underwriters); and (ix)&nbsp;all expenses and application fees related to the listing of the Shares on the Nasdaq Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If (i)&nbsp;this Agreement is terminated pursuant to clause (ii)&nbsp;of Section&nbsp;9, (ii) the Company for any reason fails to tender
the Shares for delivery to the Underwriters or (iii)&nbsp;the Underwriters decline to purchase the Shares for any reason permitted under this Agreement, the Company agrees to reimburse the Underwriters for all <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including the fees and expenses of their counsel) reasonably incurred by the Underwriters in connection with this Agreement and the offering contemplated hereby. For the
avoidance of doubt, it is understood that the Company shall not pay or reimburse any costs, fees or expenses incurred by any Underwriter that defaults on its obligations to purchase the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Persons Entitled to Benefit of Agreement</U>. This Agreement shall inure to the benefit of and be binding upon the parties hereto and
their respective successors and the officers and directors and any controlling persons referred to in Section&nbsp;7 hereof and the affiliates, employees and agent of each Underwriter referred to in Section&nbsp;7 hereof. Nothing in this Agreement
is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Shares from any Underwriter shall be deemed to be a
successor merely by reason of such purchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Survival</U>. The respective indemnities, rights of contribution, representations,
warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery
of and payment for the Shares and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or the directors, officers, controlling persons,
employees, agents or affiliates referred to in Section&nbsp;7 hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Certain Defined Terms</U>. For purposes of this Agreement,
(a)&nbsp;except where otherwise expressly provided, the term &#147;affiliate&#148; has the meaning set forth in Rule 405 under the Securities Act; (b)&nbsp;the term &#147;business day&#148; means any day other than a day on which banks are permitted
or required to be closed in New York City; and (c)&nbsp;the term &#147;subsidiary&#148; has the meaning set forth in Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Compliance with USA Patriot Act</U>. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT
STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include
the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-31- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Notices.</I> All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or
transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives c/o J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax: (212) <FONT
STYLE="white-space:nowrap">622-8358);</FONT> Attention: Equity Syndicate Desk; c/o Jefferies LLC, 520 Madison Avenue, New York, NY 10022; Attention: General Counsel; c/o Citigroup Global Markets Inc., 388 Greenwich Street, New York, NY 10013 (fax:
(646) <FONT STYLE="white-space:nowrap">291-1469);</FONT> Attention: General Counsel. Notices to the Company shall be given to it at IDEAYA Biosciences, Inc., 7000 Shoreline Court, Suite 350, South San Francisco, California 94608; Attention: General
Counsel and Chief Executive Officer, with a copy (which shall not constitute notice) to Latham&nbsp;&amp; Watkins LLP, 140 Scott Drive, Menlo Park, CA 94025; Attention: Mark V. Roeder (facsimile: (650)
<FONT STYLE="white-space:nowrap">463-2600);</FONT> email: mark.roeder@lw.com. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Governing Law.</I> This Agreement and any claim,
controversy or dispute arising under or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Submission to Jurisdiction</I>. The Company hereby submits to the exclusive jurisdiction of the U.S. federal and New York state courts
in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The Company waives any objection which it may now or hereafter have to the laying of
venue of any such suit or proceeding in such courts. The Company agrees that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding upon the Company and may be enforced in any court to the
jurisdiction of which Company is subject by a suit upon such judgment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Waiver of Jury Trial.</I> Each of the parties hereto hereby
waives any right to trial by jury in any legal proceeding arising out of or relating to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Recognition of the U.S.
Special Resolution Regimes</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event that any Underwriter that is a Covered Entity becomes subject to a
proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the
U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-32- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act
Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such
Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As used in this Section&nbsp;16(e): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance with, 12
U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Covered Entity&#148; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81,
47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;U.S. Special Resolution Regime&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the
regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Counterparts.</I> This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of
telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. This Agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with
the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Amendments or Waivers.</I> No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure
therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Headings.</I> The
headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation of, this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-33- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IDEAYA Biosciences, Inc.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Paul A. Stone</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Paul Stone</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title: Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted: As of the date first written above</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">J.P. MORGAN SECURITIES LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">JEFFERIES LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CITIGROUP GLOBAL MARKETS INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For themselves and on behalf of the</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">several Underwriters listed</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">J.P. MORGAN SECURITIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Benjamin H. Burdett</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Benjamin H. Burdett</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director, ECM Healthcare</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">JEFFERIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dustin Tyner</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Dustin Tyner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CITIGROUP GLOBAL MARKETS INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sumit Khedekar</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Sumit Khedekar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-34- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Schedule 1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Underwriter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of&nbsp;Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,047,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,904,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,523,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Guggenheim Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">761,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wedbush Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">380,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,619,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule 1-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a.<B> Pricing Disclosure Package</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">b. <B>Pricing Information Provided by Underwriters</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Price per Share:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$10.50</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of Shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">7,619,048 Underwritten Shares plus</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1,142,857 Option Shares</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IDEAYA Biosciences, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pricing Term Sheet </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">None.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">___________, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CITIGROUP GLOBAL MARKETS INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the several Underwriters listed </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in Schedule 1 to the Underwriting </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreement referred to below
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10179 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Citigroup Global Markets Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">388 Greenwich Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10013 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IDEAYA Biosciences, Inc. &#150; Public Offering </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
understands that you, as Representatives of the several Underwriters, propose to enter into an underwriting agreement (the &#147;Underwriting Agreement&#148;) with IDEAYA Biosciences, Inc., a Delaware corporation (the &#147;Company&#148;), providing
for the public offering (the &#147;Public Offering&#148;) by the several Underwriters named in Schedule 1 to the Underwriting Agreement (the &#147;Underwriters&#148;), of common stock of the Company (the &#147;Securities&#148;). Capitalized terms
used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the
Underwriters&#146; agreement to purchase and make the Public Offering of the Securities, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written
consent of J.P. Morgan Securities LLC, Jefferies LLC and Citigroup Global Markets Inc., on behalf of the several Underwriters (the &#147;Representatives&#148;), the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
undersigned will not, subject to the exceptions set forth in this letter agreement (the &#147;Letter Agreement&#148;), during the period beginning on the date of this Letter Agreement and ending
on, but including, the 60th day after the date of the final prospectus supplement relating to the Public Offering (the &#147;Prospectus&#148;) (such period, the &#147;Restricted Period&#148;), (1) offer, pledge, sell, contract to sell, sell any
option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock, $0.0001 per share par value, of the
Company (the &#147;Common Stock&#148;) or any securities convertible into or exercisable or exchangeable for Common Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the
undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant) (collectively, the &#147;Undersigned&#146;s Shares&#148;), or publicly
disclose the intention to make any offer, sale, pledge or disposition, (2)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities,
whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (3)&nbsp;make any demand for, or exercise any right with respect to, the
registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock, in each case other than (A)&nbsp;any Securities to be sold by the undersigned pursuant to the Underwriting Agreement,
(B)&nbsp;transfers of the Undersigned&#146;s Shares as a bona fide gift or gifts, (C)&nbsp;transfers or dispositions of the Undersigned&#146;s Shares to any trust for the direct or indirect benefit of the undersigned or the immediate family of the
undersigned, (D)&nbsp;transfers or dispositions of the Undersigned&#146;s Shares to any corporation, partnership, limited liability company or other entity all of the beneficial ownership interests of which are held by the undersigned or the
immediate family of the undersigned, (E)&nbsp;transfers or dispositions of the Undersigned&#146;s Shares by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family
of the undersigned, (F)&nbsp;if the undersigned is a corporation, partnership, limited liability company or other entity, distributions of the Undersigned&#146;s Shares to partners, members or stockholders of the undersigned and (G)&nbsp;if the
undersigned is a corporation, partnership, limited liability company or other entity, transfers of the Undersigned&#146;s Shares to the undersigned&#146;s affiliates or to any investment fund or other entity controlled or managed by the undersigned;
<U>provided</U> that in the case of any transfer or distribution pursuant to clause (B), (C), (D), (E), (F) or (G), each transferee, donee or distributee shall execute and deliver to the Representatives a
<FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of this Letter Agreement; and <U>provided</U>, <U>further</U>, that in the case of any transfer, disposition or distribution pursuant to clause (B), (C), (D), (E), (F) or (G), no
filing by any party (donor, donee, transferor or transferee) under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or other public announcement shall be required or shall be made voluntarily in connection with such
transfer or distribution (other than a filing on a Form 5 made after the expiration of the Restricted Period referred to above or a filing on Schedule 13D, 13F or 13G) and any such transfer or distribution shall not involve a disposition for value.
For purposes of this Letter Agreement, &#147;immediate family&#148; shall mean any relationship by blood, marriage or adoption, not more remote than first cousin. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The undersigned now has, and, except as contemplated by clause (A), (B), (C), (D), (E), (F), or (G)&nbsp;above, for the duration of this Letter Agreement will have, good and marketable title to
the Undersigned&#146;s Shares, free and clear of all liens, encumbrances, and claims whatsoever, other than any charitable pledge of the Undersigned&#146;s Shares that by its terms could not result in any transfer, disposition or distribution of
such shares during the Restricted Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, notwithstanding the restrictions imposed by this Letter Agreement, the undersigned
may, without the prior written consent of J.P. Morgan Securities LLC, Jefferies LLC and Citigroup Global Markets Inc., (i) exercise an option to purchase shares of Common Stock granted under any equity incentive plan, stock purchase plan or other
equity award plan (each, an &#147;Equity Plan&#148;), described or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or filed as an exhibit to the Registration Statement, either through cash
or &#147;cashless&#148; exercise (the term &#147;cashless&#148; exercise being intended to mean the surrender of a portion of the option shares or previously owned shares to the Company to cover payment of the exercise price), <U>provided</U> that
the underlying shares of Common Stock shall continue to be subject to the restrictions on transfer set forth in this Letter Agreement, and <U>provided further</U> that no filing under the Exchange Act or other public announcement reporting a
reduction in the aggregate beneficial ownership of the Undersigned&#146;s Shares shall be required or shall be made voluntarily in connection with such transfer or disposition during the Restricted Period (other than a filing on a Schedule 13D, 13F
or 13G), and that any public filing or announcement relating to this clause (i)&nbsp;shall briefly note the applicable circumstances that cause this exception to this Letter Agreement to apply (provided, however, that for the avoidance of doubt,
this clause (i)&nbsp;shall not be construed to in any way limit or narrow the scope of clause (vi)&nbsp;of this paragraph below), (ii) establish a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act
for the transfer of Common Stock (a <FONT STYLE="white-space:nowrap">&#147;10b5-1</FONT> Plan&#148;), <U>provided</U> that such plan is approved by the Company and does not provide for any transfers of Common Stock during the Restricted Period, and
<U>provided further</U> that no filing under the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection therewith during the Restricted Period, (iii)&nbsp;transfer or dispose of shares of Common Stock
acquired in the Public Offering or on the open market following the Public Offering, <U>provided</U> that no filing under the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with such transfer
or disposition during the Restricted Period (other than a filing on a Schedule 13D, 13F or 13G), (iv) transfer to the Company shares of Common Stock (A)&nbsp;pursuant to any contractual arrangement that provides the Company with an option to
repurchase such shares of Common Stock in connection with the termination of the undersigned&#146;s employment or other service relationship with the Company or (B)&nbsp;in connection with the vesting, settlement, or exercise of outstanding
restricted stock units, options, warrants or other rights to purchase shares of Common Stock (including, in each case, by way of &#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of exercise price and tax and remittance
payments due as a result of the vesting, settlement, or exercise of such restricted stock units, options, warrants or rights, provided that any such restricted stock units, options, warrants or rights are held by the undersigned pursuant to
(x)&nbsp;an agreement or (y)&nbsp;equity awards granted under an Equity Plan, each such agreement or Equity Plan which is described or incorporated by reference in the Registration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Statement, the Pricing Disclosure Package and the Prospectus, or filed as an exhibit to the Registration Statement, and, <U>provided further</U> that any filing under Section&nbsp;16 of the
Exchange Act with regard to (A)&nbsp;or (B) shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in (A)&nbsp;or (B) above, as the case may be, (v)&nbsp;transfer or dispose of Common Stock by
operation of law pursuant to a qualified domestic order or in connection with a divorce settlement or other court order, <U>provided</U> that the recipient of such shares of Common Stock shall execute and deliver to the Representatives a <FONT
STYLE="white-space:nowrap">lock-up</FONT> letter in the form of this Letter Agreement, and (vi)&nbsp;sell, transfer or dispose of the Undersigned&#146;s Shares pursuant to a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan that is in effect as of
the date hereof, provided that any public filing, report or announcement of any such sale or transfer shall disclose the nature of such sale or transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, this Letter Agreement shall not restrict any sale, disposal or transfer of the Undersigned&#146;s Shares to a bona fide third party
pursuant to a tender offer for securities of the Company or any merger, consolidation or other business combination involving a Change of Control of the Company occurring after the settlement of the Public Offering, that, in each case, has been
approved by the board of directors of the Company; <U>provided</U> that all of the Undersigned&#146;s Shares subject to this Letter Agreement that are not so transferred, sold, tendered or otherwise disposed of remain subject to this Letter
Agreement; and <U>provided</U>, <U>further</U>, that it shall be a condition of transfer, sale, tender or other disposition that if such tender offer or other transaction is not completed, any of the Undersigned&#146;s Shares subject to this Letter
Agreement shall remain subject to the restrictions herein. For the purposes of this paragraph, &#147;Change of Control&#148; means the consummation of any bona fide third party tender offer, merger, consolidation or other similar transaction, the
result of which is that any &#147;person&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), or group of persons, other than the Company or its subsidiaries, becomes the beneficial owner (as defined in Rules <FONT
STYLE="white-space:nowrap">13d-3</FONT> and <FONT STYLE="white-space:nowrap">13d-5</FONT> of the Exchange Act) of at least 100% of the total voting power of the voting share capital of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[In the event that, during the Restricted Period, the Representatives release or waive any prohibition set forth in this Letter Agreement on
the transfer of shares of Common Stock held by any director, officer or Significant Holder (as defined below), the same percentage of the total number of outstanding shares of Common Stock held by the undersigned on the date of such release or
waiver as the percentage of the total number of outstanding shares of Common Stock held by such director, officer or such Significant Holder on the date of such release or waiver that are the subject of such waiver shall be immediately and fully
released on the same terms from the applicable prohibition(s) set forth herein. For the purposes of the foregoing, a &#147;Significant Holder&#148; shall mean any person or entity that (together with any investment funds affiliated with such person
or entity) beneficially owns 5% or more of the total outstanding shares of Common Stock. Notwithstanding the foregoing, the provisions of this paragraph will not apply (A)&nbsp;if the release or waiver is effected solely to permit a transfer not
involving a disposition for value, (B)&nbsp;if the transferee agrees in writing to be bound by the same terms described in this Letter Agreement to the extent and for the duration that such terms remain in effect at the time of transfer, (C)&nbsp;in
the case of any secondary underwritten public offering of shares of Common Stock (including a secondary underwritten public offering with a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
primary component), (D) if the release or waiver is granted to any individual party by the Representatives in an amount, individually or in the aggregate, less than or equal to $1,500,000 in
value of Common Stock, or (E)&nbsp;if the release or waiver is granted due to circumstances of an emergency or hardship as determined by the Representatives in their sole judgment. The Representatives shall use commercially reasonable efforts to
promptly notify the Company of each such release (provided that the failure to provide such notice shall not give rise to any claim or liability against the Representatives or the Underwriters).]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the registration or transfer of the securities
described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement. All
authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. This Letter Agreement may be delivered via facsimile,
electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly
and validly delivered and be valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not
provided any recommendation or investment advice nor have the Underwriters solicited any action from the undersigned with respect to the Public Offering of the Securities and the undersigned has consulted their own legal, accounting, financial,
regulatory and tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Representative may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in
connection with the Public Offering, the Representative and the other Underwriters are not making a recommendation to you to enter into this Letter Agreement or participate in the Public Offering, and nothing set forth in such disclosures is
intended to suggest that the Representative or any Underwriter is making such a recommendation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that if
either J.P. Morgan Securities LLC, Jefferies LLC and Citigroup Global Markets Inc., on the one hand, or the Company, on the other hand, informs the other, prior to the execution of the Underwriting Agreement, that it has determined not to proceed
with the Public Offering, if the Underwriting Agreement does not become effective by September&nbsp;30, 2022 or if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to
payment for and delivery of the Common Stock to be sold thereunder, the undersigned shall be released from all obligations under this Letter Agreement. The undersigned understands that the Underwriters are entering into the Underwriting Agreement
and proceeding with the Public Offering in reliance upon this Letter Agreement. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note to Draft</B>: Only to be included in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement
signed by Canaan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement and any claim, controversy or dispute arising under or related to this
Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>]
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>IF AN INDIVIDUAL:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>IF AN ENTITY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>(duly authorized signature)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>(please print complete name of entity)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:
<I><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(please print full name)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(duly authorized signature)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:
<I><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(please print full name)</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" align="left">Title:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(please print full title)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to IDEAYA Biosciences, Inc. <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</I>]
</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d382258dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g382258dsp00.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140 Scott Drive</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Menlo Park, California
94025</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: +1.650.328.4600 Fax: +1.650.463.2600</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">www.lw.com</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FIRM / AFFILIATE OFFICES</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Austin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Milan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Beijing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Munich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Boston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Brussels</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Orange&nbsp;County</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Century City</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Paris</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chicago</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Riyadh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dubai</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Diego</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">D&#252;sseldorf</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Francisco</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Frankfurt</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Seoul</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hamburg</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shanghai</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hong Kong</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Silicon Valley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Houston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Singapore</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">London</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tel Aviv</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Los Angeles</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tokyo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Madrid</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Washington,&nbsp;D.C.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;19, 2022 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IDEAYA
Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7000 Shoreline Court, Suite 350 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">South San
Francisco, California 94608 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-254606</FONT> on Form <FONT
STYLE="white-space:nowrap">S-3;</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Up to 8,761,905 Shares of Common Stock, par value $0.0001 per share </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the addressee set forth above: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
acted as special counsel to IDEAYA Biosciences, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the proposed issuance of up to 8,761,905 shares of common stock of the Company, $0.0001 par value per share (the
&#147;<B><I>Shares</I></B>&#148;). The Shares are included in a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act of 1933, as amended (the &#147;<B><I>Act</I></B>&#148;), filed with the Securities
and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) on April&nbsp;20, 2021 (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-254606)</FONT> (as so filed and as amended, the &#147;<B><I>Registration Statement</I></B>&#148;),
a base prospectus included in the Registration Statement (the &#147;<B><I>Base Prospectus</I></B>&#148;) and a prospectus supplement dated September&nbsp;14, 2022 (together with the Base Prospectus, the &#147;<B><I>Prospectus</I></B>&#148;), and an
underwriting agreement dated September&nbsp;14, 2022, by and among J.P. Morgan Securities LLC, Jefferies LLC and Citigroup Global Markets Inc., as representatives of the several underwriters named in the underwriting agreement, and the Company (the
&#147;<B><I>Underwriting Agreement</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is being furnished in connection with the requirements of Item 601(b)(5)
of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the Prospectus, other than as expressly stated herein with
respect to the issue of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such counsel, we have examined such matters of fact and questions of law as we have considered
appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining
herein as to the General Corporation Law of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;), and we express no opinion with respect to any other laws. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>September 19, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Page 2 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g382258dsp2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date
hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company against payment therefor in the circumstances
contemplated by the Underwriting Agreement, the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely
upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated September&nbsp;19, 2022 and to the
reference to our firm in the Prospectus under the heading &#147;Legal Matters.&#148; In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and
regulations of the Commission thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Latham&nbsp;&amp; Watkins LLP</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>idya-20220914.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 9/20/2022 12:10:38 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:idya="http://www.ideayabio.com/20220914"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.ideayabio.com/20220914"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="idya-20220914_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="idya-20220914_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>idya-20220914_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 9/20/2022 12:10:38 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>idya-20220914_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 9/20/2022 12:10:38 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="idya-20220914.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g382258dsp00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382258dsp00.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M/DX& 3D\TG)+=FD:4Y1<HQ;2+#,J*69@J@9))P!3V,TKZ(S/^$FT'_H-Z?\
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MM^[G_@./RK:A*\->FAYV9T?98E\NTM5\SFO#EC'XOU[Q]]I)\NX9;5&'8*6
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
(4 % !0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g382258dsp2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382258dsp2.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MG!>9Y?BZ=7B&I7R3^U*$*D75C3X8EBH8?V]-/FB\3*K2J1<TE4C&ZNKVZ?\
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M.=@+J*"XC49^9.7-<!+'8S!QY91C"EB+54G:E5_=2I2;6GQ1^%_$DT>_X?\
M%M+A3AOB6M[:C*O7Q^3J>!G*"J8[ VQU+'TJ<97E_!K6]K!/V,Y4Y/L^CU;6
M_B;\3_V3/BYHOC'P#X@T7XMVOP^\?>"-:T"'1;T6_B?Q-;:!?6,&L>!V2$IK
MVB:T[PSVK61E59)WM@7\E7DUG/%8K)\93K8>=/&1HUJ4H<KM.:@TI4M/?C/1
MQY;V;<=;7?!AL+D/#_B-PUBLLSC#XKAN>99=CJ&(=>GS83"RQ-.I*CCTY7P]
M?"I2C557E;C&-5J/,XQA^(GA#Q5?_#7]D/3;'PYK5W?>%?BW\ =3\465OI]Q
M+<^']+T30+VWUN^UF%$+6-E8RR+'<R2A5C+A7(S4XJC6EA<EA&E*4J&)P<JB
M2=X1A!J;DOLJ.TF]C;(\SR[#Y[XF5ZN.H4J.8Y-Q%1PDY5(J.(K5\13EAZ="
M3=JDZJ3E2C&[DE='CWP[^"OC[X6?M>^'M!T[0-6NO@5H=K\5O&7@+7(+.XET
M3PD?B=8Z*=:\#37B(8=.2UU_P_++9VSR!FAOUE 9IWV\>&P.(P>=4J<:<GE]
M)8BI1DD^6G[=1YJ5]H\LX7BKWL[]6?2YUQ5DW$'AGC<77QE&GQ?BYY1@LPH2
MG%5\8LJJ5_88]0;YZKJ8?$J->HH\JG3Y-%"-]CX\^'(_'7Q8T9_A7\'/BMX9
M^/'A[QOX4A7XW6_AJ\\+> )O"5A>:;<^(;G7/%XO$T_QGHK>'VGLDL)(I[R2
M6$6R(88GAFO,*?UC&4_JF"Q%',*56FEBE3=.C[-.+FY5+J-6/)[O*TY-KE2L
MFGQ\(8R63\-XK_6#B?*,?PAC<#BI/(98J&+S%8R<*L,-'#X+DE6P-=8BU5UE
M*%",9>UE)3E&I#ZO\3_"K4]>U?Q9J%CXR?1[/Q5#X3GETYO#UEJ+6.N^#-1L
MM1T;5(KR:\B::U+6,:36,D>V0.Q65":]BKA)3G6E&MR*M[-\O(G:5)IQ:=UI
MI9Q:^:/SO <0T,'ALMH5<L6)J9<\9&-3ZQ.GST,;2G2K4G!0DHS7M&X58N\6
MDG"1O^$/AQIWAG7-?\6WMR-;\8>)98'U+77M39"*%-%\-Z5=66F:>MU-#IMG
M=3^&;*\F2([Y)%A69Y1:0E-*.&C1G4JM\]:HU>5K?9A%J*NU%-P3=MW:[=D<
M699W6QN$P>74H?5,MP$6J5!3Y[OV^*K0G5J<L959TXXJI2@Y:1BY.$8^TFGZ
M/72>(% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140300821288416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 14, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001676725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 14,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IDEAYA Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4268251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Shoreline Court<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">443-6209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IDYA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>d382258d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="idya-20220914.xsd" xlink:type="simple"/>
    <context id="duration_2022-09-14_to_2022-09-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <startDate>2022-09-14</startDate>
            <endDate>2022-09-14</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2022-09-14_to_2022-09-14"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2022-09-14_to_2022-09-14">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-09-14_to_2022-09-14"
      id="Hidden_dei_EntityCentralIndexKey">0001676725</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-09-14_to_2022-09-14">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-09-14_to_2022-09-14">2022-09-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-09-14_to_2022-09-14">IDEAYA Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-09-14_to_2022-09-14">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-09-14_to_2022-09-14">001-38915</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-09-14_to_2022-09-14">47-4268251</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-09-14_to_2022-09-14">7000 Shoreline Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2022-09-14_to_2022-09-14">Suite 350</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-09-14_to_2022-09-14">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-09-14_to_2022-09-14">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-09-14_to_2022-09-14">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-09-14_to_2022-09-14">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-09-14_to_2022-09-14">443-6209</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-09-14_to_2022-09-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-09-14_to_2022-09-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-09-14_to_2022-09-14">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-09-14_to_2022-09-14">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-09-14_to_2022-09-14">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-09-14_to_2022-09-14">IDYA</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-09-14_to_2022-09-14">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2022-09-14_to_2022-09-14">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( "&",U5ED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  A@C-5)!Z;HJT   #X 0
M&@              @ 'Y$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    "  A@C-599!YDAD!  #/ P  $P              @ '>$@
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   H%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d382258d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName -  d382258d8k.htm 7</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="d382258d8k.htm">d382258d8k.htm</File>
    <File>d382258dex11.htm</File>
    <File>d382258dex51.htm</File>
    <File>idya-20220914.xsd</File>
    <File>idya-20220914_lab.xml</File>
    <File>idya-20220914_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d382258d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d382258d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "idya-20220914_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "idya-20220914_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "idya-20220914.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "idya",
   "nsuri": "http://www.ideayabio.com/20220914",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382258d8k.htm",
      "contextRef": "duration_2022-09-14_to_2022-09-14",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d382258d8k.htm",
      "contextRef": "duration_2022-09-14_to_2022-09-14",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ideayabio.com//20220914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-22-247108-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-247108-xbrl.zip
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MIWS2QNY,Q+^YZS+?_(8N5X;_"7??%'[137^! /[58TXDN)IV)\Z(^D-V1<<
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MY].:^48PJ?\E*I,$&G$V #<R*8.X-F40FP8HIQ7S;\OI?WGN[/]02P,$%
M  @ (8(S51KSB>D%EP  *R # !    !D,S@R,C4X9&5X,3$N:'1M['WI<]M(
MDN]W1O!_0/3;G9 B(+4.7]WN=3Q9/L:[=MMAN[=WWC>0!"6T28 #@)(Y?_W+
MLRH+!TG)DF5O>&.C1R;!0AU9>><O?_O[QS>OG_SV]^<GSYX,![]]?/7Q]?,G
MS_]G[W#_\+>?^5_P\<_R??3;T[?/_A$]?7GZ]O7;]__QTY]_?_7Q^4]/HN$
M'CI-\SHMG_SV[-5_1Q\^_N/U\__XZ3*;U.>_/MJ_G^4_1<DL.\O_XZ=9.JU_
MHK'>Z6/SI#S+\KVZ6/QZL*@?1_+O45'7Q9P_FA9YO5=E_TI_/?3_GB;S;+;Z
M]6,V3ZOH]_0R>E_,$WC3R>M7+W__CY_*[.P<7O7;TR?//Y]GHZR.8%71;S\_
M??+;S^]P65T3>'!+$TC'RSHK\NB_T[+"_]5I=&_#X=$-3F-,!_/3DU?/GI_\
MXV0X>)H5U3A+\W%:Q=&K?+P??>6)/(P?'/X2']Q[%'TX3TIXM)A&I\5\#MOR
MH2[&GZ(UYW,K$_KMCR=_Y).TO"RS.LO/HI.S,DWG\"7,Y(]UU'*CLQ%R^9 N
MZG0^2LN_Y:-J\?CP7AP='1P=K3ND1S<PBR?_N?]N/WKS]OW+D]^C#\]/_WC_
MZN.KYQ^&@]>O3]>\^R8N[)/_?/[BQ?/W\+;H*[SL%-;U\OW;/]Y%+U^_?7KR
M.GIS\OZ_GG_\$+WZ_73_UDGOR4D5O4\70/5 7DF=73#YW_*:Z_,TJM*+M$QF
MD:-TX$31+*OJ=!)E^;J%W\@4/HS/T\ERED:'T7E:IG5QVUSGR?CG(F*B+LJS
M!'@+\&"\X/"4DMEM+OCXT7'T)IED%;"UDXLT7Z:W?<KXYS^*\E,<Z5_1X<'A
MPU]NGZAIJ]/I-"WM[M[B4N\?'71M[FV>9^?N;F#,-[:YIT"W9V6Q7$0O9\4(
M;O&;I/R4UI67W[=+RH^BER 2\\ML? XR&OZL[X28#PZ/;Y^87P-=P2=)/HE>
M I.>H2;PZW5.N4X_UWL9L-N\_O7>OU]Q%JRM1599&P[PM.,HB9ZEL^025*=H
M7)2+HDQ(M=Q!+O^W_W-X[^%CT*862;["?SQZO!M'B[)8%!6\ -AN5E5P6W!U
M53J;X2=6.BR[I4.;>YNW68GB7CDMRNCRO)A'JV(9X523,>E62165#?EGAFJ(
M1AUM. #^G9R!6G:6U"D*3*]#5DZ''+,.6:$."6M.RN@BF<%:_^U@_P!()UJD
M)3\=[;AM<DJGFS@,A/.1+>Q<9YWFHKK*K_;A'D;)9)+A0<3![_NW'@ZRID>+
M!9V?O-CN)BP<KCS\,O'#PR$=QH?WCN)']Q^:Q0<*=/\:WO*[&K/_:-_K5T=3
MQ=\&OZ+31"H NBA3X/DET C.L8K\>_C1?7X#C;_=5&&<43H<%,NZJN'M1#%3
MV(KH++O ?Z"0&=>.:I-9JB.8R=E9R43#R>&;=6Z-BVTNJ;W7_7SMIR>LJ M?
M^AGL7S 9Q!H&.Y?^_[<%D.5JEH:,(YVWQL./%LE9NC<JT^33WBB%>Y3^FLPN
MDU6%9O-O?W\??7CU_V"BQS_ID&2-__I_?J'_^RGZ\]6SCW__CY^ 6_Z[LRU.
MG__^\?G[KV*J?Q'7^VA( 4]NM();G4^S<EY%&8B[Q%EFEUE]'O7JM?"C<5KF
M2#'PS'"P6);C\Z22R]>BFACI8UK,9L5EM8[5]WD'OFC-AR# _WCR/CT#;BNL
M_ /P/UHFVI]\/=VNP$R!1P)W _K&U4RS&?SEML-HN?#M</#\,RP\/Z,!YL"
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M!3Z?+.'C$F?/R@MF6%, ?AJZN.F[E>SE O:P ,O#,S=TY>9I)L*L?19Y\/O
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M80$?OJY:5<@S8C8I)TMJWXX7!$S-&I/T6!WRF.*VFCW(=4('MR$B=\GT-NJ
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MEA/D*E7DX?,>4"'>[C ?!(<8?OG+P_M>99Z0&\V@C'7U3\=MC3F;A345"_#
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M>" :_%S[UE"YY_,_=J.C@\,'/S]X^(M/[CC%G(6BS+.$>BLMX39C32HMX)O
M]SX_]P _0"_3Y2QZEZP8?(KK\=JY%;%+KE!$'@?(0P3N,E0;'#COJ<EKR WD
MU6<D^%QPVFNU?#]:Q1-T<;D*+X=;>9[,IFW#W* J$]/A"C?QF5#NCT<47.IN
MV!![')UE4\0Q0G)&)AL8EL.!^Q'IW@W:1=+GI"KR]:BW3":D?9/8@81-[\84
M%IXN2QS;-Q]E\!NRI^=9U544.S5'8_&7_)H6?,*4C",!=_%2:;$:5BH6<RS>
M&1MFP*><,4_04PZ\JBW^L>? 53U>C>;/%BQM%<9?F 2C1D2VA9VK5=+3'XO1
M(/O!<P)S*!FKFP__WU)"TH&8[(=U1^.@5>4/L]XQ7.IL(LH,E1W);YCT ]>G
MJT#C3):N!JFN]9].ZX5L_2DK"\ F&&^O,FG8#T,8'JW@"EB^X==D=*MVH1[X
MM\]/GR$SPHP">CV^<CYB.GV*%?8E;97.1WH<O)6M0(4E)X0U?U;.1?G1>*0%
MA&4N_EZA7.H=Z>(5^CI<(3#/ ]T+:9;P7S E($.'Q$(<P*P6JS/  I$IE_QO
M4;9P:; ;TJOVPERSF*\0UP:!\C?A"DP@=BD #J_@<-"Z@X8]T-L]>_*?\[W:
M""G +H<1%Y8G*Y@9_F0Z6]).R46-HT_9^-,H&7_J>!.5';.WIN-BMR.1F?86
M12!-Y\SW@*%QI #4'(\E&SAP_/MG>Q51&_U"3E6(RB_!VPV*2W"NY&QO'^QW
M;8K?_V&*WYI&@X6.'?4T)TA";XH\746O$^) '$FY-+DIWL_91 J(U*#S:K^'
M?42<"0>PVE6A;,K$C:,8_>*?TG2A,4_OG \+PBVF:5%YA8GA(OB"*+.V#-@$
MC+P$:0"Y-:+16'RX&@YF?H/4>E#+[2_0MZN)0@![^ K=)]D5:[I12*X3*,ZG
M.,LM7['&Q'S8-45HE<SCMR9<Q( XL2NJ2,7)*4RJN\L8JICCIKO#PM'U$XSS
M@4@"OP6>YJ1>5P#*P!5\)T7?E(:G'9.)PV9GHV+BZJ=,>U2.;330\#N3!OM7
M8*IJ!2B#5[X-G/_=VRQ__=5J5\[K_^!*9K7@$IY:DQO.Y6C#00>PJ-5PJ_B.
M39?,NJXXSX-+@*3.OD8 .H>0Y@N'UUT(,D\)Q\CH]SL;M!72'VF'K(9XPE[+
M4TVZ$1T.QWZ&\>!:$8KQXX_HQEJ6*YU[QV,4FI8@T,;IL*8A[JG*9;-3IH
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MJ9(VJZMT-B4YE7S6<%?/"!F"-6L5AU]&5:C<_@8R4;@+W/.$0FZ5=Q-YV(]
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M*#19+**W6-VH35*_&)I!&" Z%UW:3RRZXCJXB4WX1KU:KK[/L0_!=2Q\A[)
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M,/7%,X5<Q & ;=]J7M="YE;-\'SA>*+CXP7TC<8[LF]OE0N*W&7HT_:-NW9
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M:'4ZO?MZH_WY^B*3S^CO]_5F,_K^T&[V;RXRA7S^?89<WG6;K:X>#V4P(X<
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M;!)RYD@?*(86A>NX:SF!C?*Y (&,>Z%:>.&J)SWO1Y$;!:!&J>7O,2N0W.?
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M_61S P#UY5WS&PSJ7\']'U!+ P04    "  A@C-5,OG U44#  !7"P  $0
M &ED>6$M,C R,C Y,30N>'-DO5;?;]LV$'XOT/_AIJ<.J$3):8I:B%-D30,$
M2-/"38>]%;1T=HA1I$922?S?]TA)CNS$GI,,\XMIWGUWW_VDCS[>51)NT%BA
MU23*DC0"5(4NA5I,HL;&W!9"1!^/7[\Z^BV.X?3L_!)BN':NMCECM[>W23D7
MRFK9.+)@DT)7#.*XU_]T]0/^;*WG,$6)W")4W#HT\$<C9)F/TM$HS;+#)!L-
M<0:Y-P@E=YC#F(U2YC4A&^59FA]\@),O\#G847 E*AQB=;TT8G'MX$WQ.P34
MJ58*I<0EG G%52&XA.\]Y[=PKHH$3J2$J8=9(FK1W&"9=%;O;)G;XAHK_OH5
M &5,V5R1R:::1#X572;N9D8FVBQ8Z0QSRQH9*<6DA484T0#Z[[@'&"J%E]@5
M<,[M+(!ZB<]/%J=9?) -<*)<\C5GHD2^Y#.A0ZE"]L?9NP&B1+$"!&86BV2A
M;Q@)@H^!KI>+QV,9I>D!H\YPE&X<0*10?^] >/&,FF3HY 'D]B  LO%XS()T
M@U+IUB/HK!^R5ABTN7-&S!J'9]I4ISCGC214H_YIN!1S@670HHZM4+DUG74-
MQ\T"W26OT-:\P*?EFAKKL<"(:\;^^G+Q/?1<=.P! *$-155KXZ#MQ@M=A"G9
MD4__*^[+$/NK.!M1BR1D+ +U*.TM-03V8B)]=9]%9-4:>Q.QVUK8'V)_V.;]
M\<9_=@8V!]O'/_;Q9^_WBO_!8O@/F&AU^5(R@^WV_)HH+HIV>;7'_>MRCWQ1
M;_9KP>?A<*?CS3W2>0T^N5+:!4=#)KRNA9KK[HHN?1/G?2=/<0YA?^7<%$9+
MW+WE6&UTC<8)6O;WP] :N#8XGT1^V\?]GODI^2RA/=.K/'"P/EY>S B"\N*>
M7H]UPGGPA1>#E].KR>7*M&^'260I[W(PGO]SN+7!IX9+$$OK/91M>]3?!EI/
M#M[[N2(-\(<?T_,=#\3JA6".WVFEJV7+\E07C7^%^N\357Y6Q&UY3JUEJL K
M D%/R934?^ZEOF+9\RR1_L>)T+]9ZC_T-Z^W,#QR54)K#@;VCMBFD4W[C<7R
MJSH.YX++HI&KK'?@3F,7<+->^R/OF6W'=;=]Q?HY9IN#W-T,![Z]:A<._?P%
M4$L#!!0    ( "&",U4[NEN:K@8  *9)   5    :61Y82TR,#(R,#DQ-%]L
M86(N>&ULS9QO;]LV$,;?%^AWN'EO-J"R8P<#%B-ID3G)$#1M@L3=A@U#(4N,
M34PF#5*.[6\_4G]J.:9D*CQ5>=%6D>Z>NT?YG2M+ID\_K.<1/!$A*6=GG7[W
MJ .$!3RD;'K664K/EP&E'9"QST(_XHR<=39$=CZ\?_OF] ?/@XNKZ\_@P2R.
M%W+8ZZU6JV[X2)GDT3)6DK(;\'D//"^/'XV_P!]IN2'<DXCXDL#<ES$1\-N2
M1N%P<#08'/7[OW3[@V*>(+X6A-"/R1!.>H.CGHZ$_F#8/QH>_PKGG^ RT6$P
MIG-2S.6+C:#360P_!3]#DG7!&2-11#9P19G/ NI'\)#W_ ZN6="%\RB">YTF
M5:.2B"<2=C/5B++_AOJOB6X?WKX!4.>1R63?64>?C>QDK"<BZG(Q5<T>'??R
ME,XV8[V7LCI.$OHG)R>]Y&@Q6E)3K!+O]_[Z=/,0S,C<]]3Y5[^O("LCZ5 F
M^V]XD)Q#BP:A-$+_Y.5AGM[E]0?><;^[EF'GO2Z8G1U_0J(;M06)AZ'@$:DH
MK \GU3M9?+Q9J'BRC@D+2:;\39L'6=1,D,=45=.72$H2=*?\J1<2J@GIZPU/
M;^@.?U0_?!UQ!?SY1,;"#^+=>I$^15SD.Q,39QU#4F^W(1UW+H(=+5\$N8[:
M/. _B^@%7/W>%K&7*.;ICX+/C5UDY;CAX-=H$AG;U"2I+3W?A'E?'@YY386*
MQ@21?"D47G5^M8F?]XDR_)-K_WO:V]9^+:VJEQ!);NKVZX;D PF6@L:;RW4P
M4W[)9W].;,DTY[8$:*417A[C@FNY'A*U>0'(*X NX<QN<WT7$:[;O!O(YW/U
M>JW^Q%>1/[4E^%E22^B:6^>&@RZP&H20*/VF#%K:F<X&&BUB:=NM&XZ7+%;H
MCU09X4?7ZDIB_9%L;+$L26X)SVHKO"+(!=<*021LTPJ0E8"D!J@BS@ WV'H1
MY/K]NR%]P8.EGINQZMZ6Y-V<E@ V-L[WC[G@NJ^#1&DN#%K9&4W\-HM$6O:*
M@^$=$92'ERR\4&_,Z_+X++EE,,U6>$40!JH&06QFTQ*@:H N@H9O ZT;.;;N
M'^-BX9Y,J7ZWQ^(Z;\+,N:U>*I08X>4Q[A<*)CW<ZX1M!9PW8<WU;;A(L&X>
M ^1K%G"QX"*YY_<0J\$9\:6Z2-F,>%B3ZP-2K6)N9Y-;I[@/@84\[DSL%(2D
M(F0E0==$&I+OX,LP,R\WAS%$5S0BGY?S"1'U)J:8U^IX& QP\W%W\)]KX5*N
MU2&51P(:NU\#O59-8X Z]M?7H;I8HH\T?<KS$FI+15I%^) U;A'L#G>E,"[I
MJA3LUL+EOE$KAB%X@1^,D3@/0V5 9O_<4$;Z]<;!*-#J*%19X@<"W4>@5!07
M_TS_7;X!NA+<,JSKF,9L&-!_@9=FT!^XHC]X=>@/;-$?-('^X/NA/U[QQM!'
MLF&-?J471/1':O-6C/F*O0C\8OIKP-Y@QP3]-@P-^>>2#0&ORP 7H OAPHYM
MH IU.Q>(F"?OAV_%G>!/E 4U;^N4:;P&X,N,F:A_%HN&OE&W(?[3&QL*G;P:
M[A T8J5J$FKX01R'.RYC/_J;+NK?XS0KO(91,)LR#<).)-H8&%0;&H*T$JA2
MF/<MF[-1-0#67AP_S*H-"N+7 7XWIZV/LIH:Y_O'G#[(NJ>#!&[R_[Q6QN$4
MO\^=#[%:-NL&HOYT>70WXZSF_?+]O): +#7 S<==P#1K(<&9B$.BCG7?L)E^
MBY#6:=H-U#\%C6/"1GP^7[+L?J2TI;4DN25DJZWPBB 7>"L$D0C.*L!N"6>*
M&VR\B'+=[AV7#O"(!C2F;/I)77$+ZD>V+)LRVUHV4&Z"ET4X+1DH44/B=RL/
MN;[[:H&&6MY9*U"G;S=L[P31\T$4%LDG(?4R+W'[^&A_X5"ET!+&%J;XH4@7
MK ^I(N&MRD"Q#J2%(*GD#'K3)HK O] )*OK74BZ)<!\ @\[K&(-R@^9AV(M'
M'(D2[:8&(RW7Z'PTY*AR2FK9PED9V1],QC2.:J^*W.:UO")RSP W'\=8";FK
MA751DR\D5.J0R*.M@,3MU[CZT:)I-U#'PM??FO"PF4^X]27XLZ26$#6WS@T'
M7> T""&1F2E#*NU,90.-%I&T[1;CL<CEG(BI*O:[X*MXIE[#%SZKN?ZQ1*+5
M!R/5MOC!4/='(Q6RN,]&\D*05H*L%-*CD09M&)Z-U/:",@)K-7!,4GT3)EU(
M5)-_0WZ[\)<;XM5Q"-B7:"(SOX9MF6SU%Q;P#1DPT6[CHKCC1FWI;Q?*=M'T
M.W;4GO\!4$L#!!0    ( "&",U4*CRT-X00   ,N   5    :61Y82TR,#(R
M,#DQ-%]P<F4N>&ULU9I=C^(V%(;O5]K_X&9O6JDA),RT"QIF19F9"I7Y$+!M
MU9N520Y@U;$CVPSP[VL'W"409LGLMHKG8@#'[_'K\Q@G-K[ZL$XI>@8A"6==
M+VPT/00LY@EA\ZZWE#Z6,2$>D@JS!%/.H.MM0'H?KM^^N?K.]]'-W> !^6BA
M5"8[0;!:K1K)C##)Z5+ID+(1\S1 OF_K]R<?T>_;YCIH!!2P!)1BJ4"@7Y:$
M)IVH&47-,+QLA-&^3@ V 5&"%710.XB:@:F)PJ@3-CNM]ZAWCV[S. Q-2 K[
M6IYM!)DO%/H^_@'EJAO.&% *&W1'&&8QP12-K><?T8#%#=2C%(V,3&JC$L0S
M)(U=5$K8WQWS;VKLH[=OD/[3F60R+^UZ)A^[=*RG@C:XF&N[S59@1=Z^9GTD
M6K5R2=ANMX/\:K&^)&6U=0-A\.?]<!PO(,6^IJ"IQ0=-:3>)^E>];^XRV%ZT
M]27IR#S2D,=Y[L_H%CI9PWSR;37?%/EAY+?"QEHFWK5I<IM5P2F,8(;,Z\?1
MH- F20!O\)3P?%3E_)OM\")0>,T93S>!$04W/%ZFP)1][;'DEBFB-@,VXR+-
MN^*A/*N=A8!9UR/)!OLVFC'T;J0#?:H22&TR_=60),TH>"C8ZU F].!A*J\]
MU 4% :P5L 02&\9TX+_J\O66ZV[P\KB0 OL%SJ%)B!MS_APD0$R+H7EC\I/#
M>J<_?.IS/6?TIE()'*MB#J@9+5S80HJG0+M>B2CXEH;&$"^%[O#M.EY@-H<'
MG,*YOLJU17O[%'LB+D3&(K91]=LCA,7OP:Y&D&&AX_GQ0L]Y5CT3/"U-U:XU
M_I)?+A(072^*&GH:\% F"#>5=(F'EE);XIDQCZFY!C,0 I+A-@DGS>9.]90J
M(:_YC9GU]%!-S'"]HWA^+JP#47TI'1BU>%K.X-G.('W= X'I0,]2Z]]@<RZF
M$^+ZXCIAV&*[< :;O0=,=!K/I574U!=2T:=E\Y-S;)Y >]6WZ.1&/\U6A70@
MKC^M \,6V\_.8-O.#2.8$]-1IJH\7)1KZPNMW*]E]MXQ9GHAQT7&19[:L<XP
M]/E23_&;/D\J(OQ"J+H3_8)]"[CM&. [0N%AF4Y!5*.YKZL[NGVO.TZMIF.<
M)G@]2'0:R(QL-Q-> ^UDD+H3/&G<X@P=P]E+$IUDN7L9$@9A-92E >J.L=2T
M1>C.NOM49Z*O11BYB##ZC-"UM?FN%WW]]E%,^(J]"N"^W!%\^Y8M/'=6Z(6N
MY(]BC^))\&=B-NM?0_ HAB,8CWQ;EI=NLGSB4F'Z%\FJKR[*(SC"\<"UI>C.
MOHR93WH"<!5N14U]215]6C;N;+Z87Q_ITX*SBNN\8UU]&1U[M9S<V7#Y0_M3
MP/H\39=LM\R1Y\(Z(:XOL1.&+39WME'&G)*8*,+F]_IF+(BQ=N;/IB7*^@(K
M<[NC=>'.9LJ3 #/D0#\MY;^#F,,#XG$V.W]:?"E"?>F]Y-I2=&</Y: W RF7
M(+Z>94D<9XB6>+=<W=E8L0<SPF@Z(8I6/H#R65=?;L=>+2=W=D\F IL#CN--
M.N5GW^X.1/4E=&#4XG%M?^0V!3'7_?A5\)5:Z+DBPZSB\9,3(>J+[D7;%J1K
MFR.W:STBF23&W/8H0$6*)?K:(RSQ;/G]#]LB5\%17H:ZP!Q=WEXQ_\Q!7%WR
M#U!+ 0(4 Q0    ( "&",U5DQP#*0A(  .5Q   .              "  0
M  !D,S@R,C4X9#AK+FAT;5!+ 0(4 Q0    ( "&",U4:\XGI!9<  "L@ P 0
M              "  6X2  !D,S@R,C4X9&5X,3$N:'1M4$L! A0#%     @
M(8(S5<1..5I/"P  ##<  !               ( !H:D  &0S.#(R-3AD97@U
M,2YH=&U02P$"% ,4    "  A@C-5,OG U44#  !7"P  $0
M@ $>M0  :61Y82TR,#(R,#DQ-"YX<V102P$"% ,4    "  A@C-5.[I;FJX&
M  "F20  %0              @ &2N   :61Y82TR,#(R,#DQ-%]L86(N>&UL
M4$L! A0#%     @ (8(S50J/+0WA!    RX  !4              ( !<[\
L &ED>6$M,C R,C Y,31?<')E+GAM;%!+!08     !@ & 'T!  "'Q      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
